Method and composition for targeted delivery by polymer pores

The polymerosome with a glycan head and guanidine/zwitterion copolymer addresses the inefficiencies of conventional polymerosomes by enabling selective and stable delivery of nucleic acids, enhancing therapeutic efficacy.

KR1020260164451APending Publication Date: 2026-11-17락 바이오메디컬 인크
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020257008467
Authority / Receiving Office
KR · KR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-04-05
Filing Date
2024-04-08
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Conventional polymerosomes lack the ability to efficiently encapsulate and deliver therapeutic agents, such as nucleic acids, to specific areas of an organism, and are unstable in serum, limiting their effectiveness in targeted drug delivery.

Method used

A polymerosome design featuring a copolymer with an initiator block containing a glycan head and a propagator block with guanidine and zwitterion groups, linked by a disulfide bond, enabling selective targeting and efficient encapsulation, stability, and controlled release of payloads.

Benefits of technology

The polymerosome achieves selective delivery and enhanced encapsulation of nucleic acids, with improved stability and controlled release, facilitating targeted therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure P1020257008467_ABST
    Figure P1020257008467_ABST
Patent Text Reader

Abstract

The present disclosure relates to copolymers and polymerosomes for the targeted delivery of biomolecules into living organisms. An exemplary copolymer comprises an initiator block, a propagator block, and a link connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide targeted delivery, and the propagator block comprises a functional moiety configured to provide the desired properties to the polymerosomes.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] Cross-reference regarding related applications

[0002] The present application claims priority to U.S. Provisional Application No. 63 / 458,102 filed April 8, 2023, U.S. Provisional Application No. 63 / 587,231 filed October 2, 2023, and U.S. Provisional Application No. 63 / 575,056 filed April 5, 2024, the full text of which is incorporated herein by reference.

[0003] field

[0004] The present disclosure relates to compositions and methods for pharmaceutical formulations comprising, in general, polymer nanocarriers, particularly polymerosomes capable of selectively / targetedly delivering a payload to a desired target area within a tissue or to a cell. Background Technology

[0005] Nanotechnology-based delivery has been widely used in scientific, industrial, and clinical applications. It has become a promising method for drug delivery, offering benefits such as improved solubility and penetration of drug molecules. In a recent example, mRNA vaccines developed against the COVID-19 virus utilized specialized lipid nanoparticles (LNPs) modified to encapsulate and stabilize mRNA molecules, considering that mRNA molecules are generally unstable and require storage at low temperatures (e.g., -70°C). Typical lipid nanoparticles are typically composed of several types of lipids. The ratio of these lipids requires fine-tuning, the manufacturing of lipid nanoparticles can be costly, and lipid nanoparticles generally cannot selectively deliver mRNA molecules. Therefore, there is a need in the relevant technology field for nanoparticles with a simpler composition and the ability to deliver selectively.

[0006] In one aspect, the present disclosure provides a copolymer for forming a polymer some. The copolymer comprises an initiator block comprising a glycan head and a propagator block further comprising a functional moiety comprising a guanidine group, a zwitterion group, a diethylenetriamine, or a combination thereof; and a link jointly linking the initiator block and the propagator block, wherein the link comprises a disulfide bond.

[0007] In one aspect, the present disclosure provides a polymer wool. The polymer wool comprises a membrane defining an internal space, wherein the membrane comprises an exemplary copolymer of the present disclosure.

[0008] In one aspect, the present disclosure provides a pharmaceutical formulation comprising the polymer som of the present disclosure.

[0009] In one aspect, the present disclosure provides a kit for manufacturing polymer somes. The kit comprises: a first reagent comprising an initiator, wherein the initiator comprises a glycan head and an initiator linking moiety; and a second reagent comprising a propagator, wherein the propagator comprises a functional moiety and a propagator linking moiety, wherein the functional moiety comprises a guanidine group, a zwitterion group, a diethylenetriamine, or a combination thereof; wherein the initiator linking moiety is configured to be coupled to the propagator linking moiety through a link comprising a disulfide bond.

[0010] In one aspect, the present disclosure provides a method for targeted delivery of a payload to a subject. The method comprises administering to a subject an effective amount of a pharmaceutical formulation comprising a polymerosome, wherein the polymerosome comprises a membrane that encapsulates the payload, and wherein the membrane comprises the copolymer of the present disclosure.

[0011] In one aspect, the present disclosure provides a method for preventing or treating a disease in a subject, comprising administering an effective amount of a pharmaceutical formulation containing a polymerosome to a subject, wherein the polymerosome comprises a membrane containing a polymer component of any one of claims 1 to 34; and a payload encapsulated within the membrane; wherein the payload is a therapeutic agent or induces a therapeutic agent.

[0012] In one aspect, the present disclosure provides a method for boosting an adaptive immune response, comprising administering to a subject an effective amount of a pharmaceutical formulation containing a polymerosome, wherein the polymerosome comprises a membrane encapsulating a payload, wherein the membrane comprises a copolymer of the present disclosure, wherein the payload is immunogenic or induces an immunogenic biomolecule. Brief explanation of the drawing

[0013] FIG. 1a shows a schematic diagram illustrating an exemplary synthesis of an exemplary copolymer of the present disclosure. X and Y are both integers and are independently 9 to 14. FIG. 1b shows the structure of some exemplary polymer filaments comprising a copolymer according to some embodiments of the present disclosure. FIG. 2a shows the results of an agarose gel electrophoresis assay indicating the encapsulation efficiency of some exemplary copolymers according to some embodiments of the present disclosure. In this efficacy-demonstration assay, the payload was GFP mRNA of approximately 920 bp. Copolymers with or without GFP mRNA had a size greater than 10 kDa. FIG. 2b provides a graph showing the average fluorescence intensity of HEK293 cells after transfection with a polymerosome encapsulating GFP-mRNA according to some working embodiments of the present disclosure. FIG. 3a shows the results of an agarose gel electrophoresis assay demonstrating the encapsulation efficiency of various copolymers according to some working embodiments of the present disclosure. In this demonstration assay, the payload was spike mRNA with a size of approximately 2550 bp. Exemplary copolymers with or without spike mRNA had a size greater than 10 kDa. The N / P ratio (positively charged polymer amine group (N = nitrogen) to negatively charged nucleic acid phosphate (P) group) of each experimental group is indicated by the number shown in each lane. The N / P ratios tested in this experiment were 0.01, 0.05, 0.1, 0.5, 1, 5, 10, and 20. Figure 3b provides a graph representation showing the particle size and zeta (ζ) potential of mRNA-PNP (P1 / P5) with cryo-EM images and insets. Figure 3c shows chemiluminescence images demonstrating spike protein expression mediated by spike mRNA-PNP (I1-P1 / P5) in HEK293T cells. The first lane shows protein expression from cells transfected with spike mRNA, and the second lane shows protein expression from cells transfected with spike mRNA-PNP (I1-P1 / P5). Beta-actin was used as the benchmark expression in this experiment. Figure 4 provides a graph of the co-localization of lysosomes and mRNA-PNP in cells investigated using confocal fluorescence imaging over 4 hours. Images were collected at 1, 1.5, 2, 2.5, 3, 3.5, and 4 hours, respectively. mRNA-PNP was labeled with FITC for detection. Figure 5 provides a graph representing the cellular uptake fluorescence signals of BMDCs, B cells, and T cells treated with spike mRNA-PNP (I1-P1 / P4-FITC / P5) or spike mRNA-PNP (I2-P1 / P4-FITC / P5) targeting Siglec-2 after 1 hour. Data were collected using flow cytometry analysis. Figure 6 provides a graph showing the cellular uptake fluorescence signals of BMDCs, B cells, and T cells treated with spike mRNA-PNP (I1-P1 / P4-FITC / P5) or spike mRNA-PNP (I5-P1 / P4-FITC / P5) targeting DC-SIGN after 1 hour. Data were collected using flow cytometry analysis. FIG. 7 provides a graph representation showing the binding analysis of DC-SIGN, MMR, MINCLE, Dectin-2 and Langerin (0.625 μg / mL) to a polymer some at pH 7.4 according to some embodiments of the present disclosure. Figure 8a shows a schematic diagram illustrating the design of an animal immunization experiment. Figure 8b provides a graph showing serum spike-specific IgG titers induced by immunization with I1-P1 / P5 mRNA-PNP, I9-P1 / P5 mRNA-PNP, and LNP-mRNA (control) measured on day 28 after immunization. Figure 8c provides a graph representation of the neutralization titers (ID50) resulting from the immunization of I1-P1 / P5 mRNA-PNP, I9-P1 / P5 mRNA-PNP, and LNP-mRNA (control) measured on day 28 after immunization. The neutralization titer was calculated as the reciprocal of the serum dilution that caused a 50% reduction in RLU compared to the virus control well, after subtracting the background RLU. The ID50 values ​​are labeled on the plot along with the standard error of the mean. Figure 9 is a graph showing FACS data of C2C12 muscle cell uptake of the polymerosomes of the present disclosure (at 0 and 1 hour after treatment) and polymerosomes without targeted glycans (at 1 hour after treatment). Specific details for implementing the invention

[0014] Delivery by nanoparticles has been widely used in various applications. In addition to lipid nanoparticles (LNPs), another type of nanoparticle called polymerosomes, which is almost the most common type of nanoparticle, has also been gaining increasing interest in industrial and clinical applications. Polymerosomes (i.e., polymer-based nanoparticles, polymer vesicles, or polymer nanoparticles (PNPs)) are self-assembled enclosures from amphiphilic block copolymers. These amphiphilic block copolymers are macromolecules containing at least one hydrophobic polymer block and at least one hydrophilic polymer block. When hydrated, these amphiphilic block copolymers self-assemble into an enclosure, with the hydrophobic blocks tending to associate with each other to form the inner surface of the enclosure to minimize direct exposure to water, and the hydrophilic blocks facing outward to form the outer surface of the enclosure. The hydrophobic core of these water-soluble polymerosomes can provide an environment that solubilizes additional hydrophobic molecules. Therefore, these water-soluble polymerosomes can act as carrier polymers for hydrophobic molecules encapsulated within the polymerosomes. Furthermore, the self-assembly of amphoteric block polymers occurs in the absence of a stabilizer, which would otherwise provide colloidal stability and prevent aggregation.

[0015] Polymerosomes offer many advantages, such as high stability during storage, greater manufacturing accessibility, convenient surface modification, high biocompatibility, and controlled release mechanisms. However, polymerosomes capable of efficiently delivering drug molecules to specific areas of an organism are still lacking in industry. This is likely due to the fact that conventional polymerosomes do not effectively encapsulate payloads (e.g., biomolecules administered for their therapeutic effect) and are generally unstable in serum. Furthermore, they are also unable to perform selective delivery.

[0016] polymer cotton

[0017] Accordingly, one aspect of the present disclosure provides a polymerosome. The polymerosome of the present disclosure is designed to provide selective delivery (or targeted delivery) and excellent encapsulation efficiency, particularly for nucleic acid-type payloads. An exemplary polymerosome comprises a membrane defining an internal space configured to encapsulate or transport a payload. The membrane of the polymerosome of the present disclosure comprises a copolymer comprising an initiator block, a propagator block, and a linkage, wherein the linkage co-links the initiator block and the propagator block and comprises a disulfide bond. The initiator block comprises a glycan head, and the propagator block comprises a functional moiety comprising a guanidine group, a zwitterion group, a diethylenetriamine, or a combination thereof.

[0018] While not wishing to be confined to theory, the disulfide linkage of the linkage (i.e., the disulfide linkage) is selected for its biodegradability and / or thiol-mediated absorption in the intracellular environment. Thus, the disulfide linkage facilitates the absorption and subsequent degradation of the polymerosomes of the present disclosure, thereby enabling the release of the encapsulated payload, for example, through intracellular glutathione-mediated cleavage.

[0019] In some embodiments, the copolymer may comprise more than one initiator block and more than one propagator block. For example, the copolymer may comprise one initiator block, a first propagator block and a second propagator block, wherein the initiator block and the first propagator block and the first propagator block and the second propagator block are both connected through a link.

[0020] Initiator block

[0021] In certain embodiments, the initiator block comprises a glycan head configured to provide selective delivery. To this end, the glycan head may have a targeting moiety that is a ligand of the target (e.g., a receptor on the target cell). In some embodiments, the targeting moiety may be a terminal moiety of the glycan head for a better chance of interacting with and binding to the target. Nevertheless, the present disclosure is not limited to such configurations. In some embodiments, the target cell for selective delivery is an antigen-presenting cell (APC, e.g., a dendritic cell). In some embodiments, the target cell may be another type of immune cell. In some other embodiments, the target may be any biological cell designed to interact with the payload.

[0022] In certain embodiments, the initiator block is configured to exhibit superior uptake by certain types of APCs by binding to lectin receptors, such as Siglec-1 (sialoadhesin), Siglec-2, Siglec-5 / E, and DC-SIGN, with a specific degree of affinity. In some embodiments, the glycan head of the initiator block comprises mannosidase, which may be terminal mannose configured to bind to DC-SIGN on dendritic cells. In some embodiments, the glycan head comprises sialoside. In some embodiments, to target Siglec-1, the glycan head may comprise 9-N-(4H-thieno[3,2-c]cromen-2-carbamoyl)-Neu5Ac-α2,3-Gal-GlcNAc. In some embodiments, to target Siglec-2, the glycan head may comprise 9-biphenyl Neu5Ac-α2,6-Gal. In some embodiments, to target Siglec-5 / E, the glycan head may include Neu5Ac-α2,3-Gal-GlcNAc.

[0023] Binding under acidic conditions. In some embodiments, the binding between the initiator block and the target is Ca 2+ - It is correlated, and calcium coordination decreases in low pH environments, which can lead to lower binding affinity. Therefore, to provide better binding affinity under acidic conditions, the glycan head of the initiator block may include an aryl group. While we do not wish to be bound by any theory, the aryl group may be involved in CH-π and hydrophobic interactions that promote binding under acidic conditions. The aryl group may be an unsubstituted benzene, or a benzene substituted with a halide or alkyl halide (e.g., CF3). In some embodiments, the aryl group is coupled to a targeting moiety. For example, the glycan head of the initiator block may include an O-aryl mannoside.

[0024] Structural coordination of the glycan head. In certain embodiments, the glycan head may have a linear or branched structure. In some embodiments, the glycan head may have multiple targeting moieties, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 targeting moieties. The multiple targeting moieties may be arranged in linear, branched, or stellate coordination. For example, the glycan head of the initiator block may include a mono-mannosid, a di-mannosid, or a tri-mannosid, and if the glycan head includes a tri-mannosid, the tri-mannosid may be in a linear or branched form, e.g., α-1,3-α-1,6-trimannosid. In certain embodiments, it is noted that in some situations, the branched coordination (e.g., a tri-mannosid glycan head) exhibits superior binding affinity for its target receptor.

[0025] Initiator spacer. In some embodiments, the initiator block further comprises an initiator spacer. The initiator spacer is configured to facilitate the assembly of polymerosomes by providing structural flexibility to the glycan head and / or hydrophobicity to the entire copolymer. Without wanting to be confined to theory, flexibility facilitates the bonding between the glycan head by moving it during the interaction between the initiator block and the target.

[0026] A preferred spacer is biocompatible. In some embodiments, the initiator spacer comprises a saturated carbon moiety, a polyethylene glycol (PEG) moiety, or a combination thereof. For example, the spacer is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 20, 24, 30, 36, 40, 48, 50, 55, 60, 65, or 72 (OCH2CH2) subunits, or any range defined by the above endpoint, e.g., 2 to 72, 2 to 60, 2 to 48, 2 to 36, 2 to 24, 2 to 18, 2 to 15, 2 to 10, 4 to 72, 4 to 60, 4 to 48, 4 to 36, 4 to 24, 4 to 18, 4 to 15, 4 to 10, 8 to It may be a polyethylene glycol (PEG) moiety formed by 72, 8 to 60, 8 to 48, 8 to 36, 8 to 24, 8 to 18, 8 to 15, or 8 to 10 (OCH2CH2) subunits. In some embodiments, the PEG moiety may be a linear, branched, or stellate structure.

[0027] In some embodiments, the spacer is a saturated carbon moiety that may be a lipid tail connected to a glycan head. In some embodiments, the saturated carbohydrate has at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 carbons or any range of carbons defined by the endpoint, e.g., 2 to 15, 2 to 12, 2 to 10, 2 to 8, 2 to 6, 2 to 4, 3 to 15, 3 to 14, 3 to 13, 3 to 12, 3 to 11, 3 to 10, 3 to 9, 3 to 8, 3 to 7, 3 to 6, 3 to 5, 4 to 15, 4 to 14, 4 to 13, 4 to 12, 4 to 11, 4 to 10, 4 to 9, 4 to 8, 4 to 7, 4 to 6, It contains 6 to 15, 6 to 14, 6 to 13, 6 to 12, 6 to 11, 6 to 10, 6 to 9, or 6 to 8 carbons.

[0028] Binding affinity. In some embodiments, the binding affinity between the glycan head of the initiator block and the target is the dissociation constant (K D It can be defined by ). In some embodiments, K at pH 7.4 D는 5, 10, 15, 20, 30, 40, 50, 75, 100, 125, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2250, 2500, 3000, 3250, 3500, 3750, 4000, 4250, 4500, 4750, 5000, 5250, 5500, 5750, 6000, 6250, 6500, 6750, 7000, 7250, 7500, 7750, or 8000 nM, or any range defined by the above endpoint, e.g., 5 to 8000, 5 to 7000, 5 to 6000, 5 to 5000, 5 to 4000, 5 to 3000, 5 to 2500, 5 to 2000, 5 to 1500, 5 to 1250, 5 to 1000, 5 to 900, 5 to 800, 5 to 700, 5 to 600, 5 to 500, 5 to 400, 5 to 300, 5 to 200, 5 to 150, 5 to 100, 5 to 75, 5 to 50, 5 to 30, 5 to It may be 20, 10 to 8000, 10 to 7000, 10 to 6000, 10 to 5000, 10 to 4000, 10 to 3000, 10 to 2500, 10 to 2000, 10 to 1500, 10 to 1250, 10 to 1000, 10 to 900, 10 to 800, 10 to 700, 10 to 600, 10 to 500, 10 to 400, 10 to 300, 10 to 200, 10 to 150, 10 to 100, 10 to 75, 10 to 50, 10 to 30, or 10 to 20 nM.

[0029] In some other embodiments, K at pH 5 Dis 1, 2, 3, 4, 5, 10, 15, 20, 30, 40, 50, 75, 100, 125, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1250, 1500, 1750, or 2000 nM, or any range defined by the above endpoint, e.g., 1 to 2000, 1 to 1500, 1 to 1000, 1 to 900, 1 to 800, 1 to 750, 1 to 700, 1 to 650, 1 to 600, 1 to 550, 1 to 500, 1 to 450, 1 to 400, 1 to 350, 1 to 300, 1 to 250, 1 to 200, 1 to 150, 1 to 100, 1 to 75, 1 to 50, 1 to 40, 1 to 30, 1 to 20, 1 to 10, or to 5, 5 to 2000, 5 to 1500, 5 to 1000, 5 to 900, 5 to 800, 5 to 750, 5 to 700, 5 to 650, 5 to 600, 5 to 550, 5 to 500, 5 to 450, 5 to 400, 5 to It may be 350, 5 to 300, 5 to 250, 5 to 200, 5 to 150, 5 to 100, 5 to 75, 5 to 50, 5 to 40, 5 to 30, 5 to 20, 5 to 10 nM.

[0030] Yes. In some embodiments, the glycan head of the initiator block is 9 BPC Neu5Ac conjugated N-glycan head (e.g., IB2), Neu5Ac conjugated N-glycan (e.g., IB3), 9T CCNeu5Ac comprises a conjugated N-glycan (e.g., IB4) or a combination thereof. In certain embodiments, the glycan head comprises at least one of the following structures (note that “IB” indicates an initiator block describing the conjugated initiator in the copolymer of the present disclosure. Nevertheless, “IB” may be used interchangeably with “I” indicating an initiator for brevity):

[0031]

[0032] Here, the filled circle represents the mannosid, the empty circle represents the galactose, the filled square represents the GlcNAc, and the diamond represents the Neu5Ac.

[0033] Propagator Block

[0034] In certain embodiments, the exemplary polymerosomes of the present disclosure exhibit desired properties, such as efficient payload encapsulation, reduced serum protein adsorption, enhanced membrane fusion, and efficient payload release after absorption. At least one of the desired properties is provided by the propagator block of the present disclosure. To this end, the propagator block of the present disclosure comprises a functional moiety comprising a guanidine group, a zwitterion group, a diethylenetriamine, or a combination thereof.

[0035] In some embodiments, the copolymer of the present disclosure comprises a single propagator block providing at least one of the desired properties. In some embodiments, the copolymer of the present disclosure comprises a plurality of propagator blocks, each providing at least one of the desired properties.

[0036] Efficient payload encapsulation. In some embodiments, the polymerosomes of this disclosure are designed to carry nucleic acid-type payloads, such as mRNA molecules or DNA molecules. In these embodiments, the propagator block of the copolymer of the polymerosomes may include guanidine groups. In some embodiments, the propagator block includes one, two, three, four, five, or more guanidine groups. Without being bound by theory, multiple guanidine groups within the propagator block provide a stronger salt crosslink between the guanidinium groups of the copolymer and the phosphate groups of the nucleic acid molecule (e.g., mRNA). In certain embodiments, the propagator block includes three guanidine groups.

[0037] Reduced serum protein adsorption and enhanced membrane fusion. As mentioned above, one of the common disadvantages of polymerosomes is said to be their instability in serum due to serum protein adsorption. To enhance serum stability by reducing serum protein adsorption, the copolymer of the present disclosure may comprise a zwitterion, which also enhances membrane fusion of the polymerosomes with target cells. The zwitterion of the present disclosure may be a molecule / moiety having an overall charge of zero by possessing an equal number of positively charged functional groups and negatively charged functional groups at pH 4.5 to 7.5. In some embodiments, the zwitterion of the present disclosure comprises an isoelectric point of pH 4.5 to 7.5. The zwitterion may be, but is not limited to, choline phosphate (CP), sulfotetin, phosphonium sulfonate, or psilocybin. In some embodiments, the zwitterions of the present disclosure comprise an alkylphosphobetaine group comprising a phosphate group and an amine group that provide a negative charge and a positive charge, respectively.

[0038] Efficient payload release after absorption. Another desired characteristic of the polymerosome is the ability to efficiently release the captured / encapsulated payload after absorption. The release of the captured / encapsulated payload occurs in the lysosomes of the target cell, resulting from detachment from the endosome / lysosome pathway or degradation of the polymerosome. In some embodiments, the zwitterion of the propagator block may facilitate endosome detachment. Additionally, in some embodiments, the propagator block may further comprise an alkyl chain, which also contributes to endosome detachment.

[0039] On the other hand, in some embodiments, to facilitate lysosome degradation, the propagator block of the present disclosure may comprise a diethylene-triamine moiety. The terminal amine residue of the diethylene-triamine moiety may also be used for further functionalization. Alternatively, the propagator block of the present disclosure may comprise ethylenediamine, 1-(2-aminoethyl)piperazine and / or tris(2-aminoethyl)amine.

[0040] Propagator spacer. In some embodiments, the propagator block of the present disclosure comprises a propagator spacer configured primarily to provide the hydrophobicity required for assembly into a polymer wool to a copolymer. In some embodiments, the propagator spacer comprises a saturated carbon moiety, a polyethylene glycol (PEG) moiety, or a combination thereof.

[0041] In some embodiments, the spacer comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 20, 24, 30, 36, 40, 48, 50, 55, 60, 65, or 72 (OCH2CH2) subunits, or any range defined by the endpoint, e.g., 2 to 72, 2 to 60, 2 to 48, 2 to 36, 2 to 24, 2 to 18, 2 to 15, 2 to 10, 4 to 72, 4 to 60, 4 to 48, 4 to 36, 4 to 24, 4 to 18, 4 to 15, 4 to 10, 8 to It may be a polyethylene glycol (PEG) moiety formed by 72, 8 to 60, 8 to 48, 8 to 36, 8 to 24, 8 to 18, 8 to 15, or 8 to 10 (OCH2CH2) subunits. In some embodiments, the PEG moiety may be a linear, branched, or stellate structure.

[0042] In some embodiments, the saturated carbon moiety may be a geological tail extended from the propagator block. In some embodiments, the saturated carbohydrate has at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 carbons or any range of carbons defined by the endpoint, e.g., 2 to 15, 2 to 12, 2 to 10, 2 to 8, 2 to 6, 2 to 4, 3 to 15, 3 to 14, 3 to 13, 3 to 12, 3 to 11, 3 to 10, 3 to 9, 3 to 8, 3 to 7, 3 to 6, 3 to 5, 4 to 15, 4 to 14, 4 to 13, 4 to 12, 4 to 11, 4 to 10, 4 to 9, 4 to 8, 4 to 7, 4 to 6, It comprises 6 to 15, 6 to 14, 6 to 13, 6 to 12, 6 to 11, 6 to 10, 6 to 9, or 6 to 8 carbons. In certain embodiments, the propagator spacer comprises a monocarboxylic acid amide moiety (e.g., lipoamide moiety) or other biocompatible structure, which provides a functional group for saturated carbohydrates and conjugation.

[0043] Yes. In some embodiments, the propagator block of the present disclosure comprises at least one of the following structures (note that “PB” indicates a propagator block describing a propagator bonded in a copolymer of the present disclosure. Nevertheless, “PB” may be used interchangeably with “P” indicating a propagator for brevity):

[0044]

[0045] Copolymer propagator block. In some embodiments, the copolymer comprises a plurality of propagator blocks and a plurality of connections, wherein each propagator block of the plurality of propagator blocks is connected to at least another propagator block or initiator block of the plurality of propagator blocks through one of the plurality of connections. Without being bound by theory, the present disclosure considers it advantageous to have two or more propagators within the structure of the copolymer. Each of the two or more propagators may provide at least one of the desired properties of efficient payload encapsulation, reduced serum protein adsorption, enhanced membrane fusion, and efficient payload release after absorption. In some embodiments, each of the two or more propagators differs in structure and / or the desired properties provided, thereby forming the copolymer as a heteropolymer.

[0046] In some embodiments, the heterocopolymer comprises any two or more propagator blocks PB1, PB2, PB3, PB4, and PB5. In some embodiments, the copolymer comprises at least two propagator blocks that are (1) PB1 and PB5, (2) PB1 and PB4, (3) PB2 and PB5, (4) PB2 and PB5, or (5) PB1, PB4, and PB5, wherein two or more propagators in the copolymer may be represented by the formula numbers of two or more propagators separated by the symbol " / ". For example, two propagator blocks of PB1 and PB5 in the copolymer may be represented as PB1 / PB5. Nevertheless, the order and amount of propagator blocks in the referred copolymer are not limited by the method by which they are named. Although we do not wish to be bound by theory, the present disclosure has revealed that copolymers of PB1 / PB4, PB2 / PB4, PB1 / PB5, and PB2 / PB5 exhibit excellent intracellular delivery due to efficient membrane fusion and payload release.

[0047] In certain embodiments, a hetero-copolymer copolymer having two or more different types of propagator blocks may be composed of any initiator of I2, I3, I4, I5, I6, I7, I8, I9, and I10. The conjugation of the initiator and the propagator may be represented by the formula numbers of the initiator and the propagator separated by the hyphen "-". For example, a copolymer comprising initiator I5 and propagator P5 may be represented as I5-P5. Nevertheless, the order and amount of initiator blocks and / or propagator blocks in the referred copolymers are not limited by the method by which they are named. In some embodiments, the copolymer of a heteropolymer having two or more different types of propagators conjugated to one type of initiator of the present disclosure is I5-P1 / P5, I5-P1 / P4, I5-P2 / P5, I5-P2 / P4, I5-P1 / P4 / P5, I6-P1 / P5, I6-P1 / P4, I6-P2 / P5, I6-P2 / P4, I6-P1 / P4 / P5, I7-P1 / P5, I7-P1 / P4, I7-P2 / P5, I7-P2 / P4, I7-P1 / P4 / P5, I8-P1 / P5, I8-P1 / P4, I8-P2 / P5, I8-P2 / P4, I8-P1 / P4 / P5, I9-P1 / P5, I9-P1 / P4, It can be selected from the group consisting of I9-P2 / P5, I9-P2 / P4, I9-P1 / P4 / P5, I10-P1 / P5, I10-P1 / P4, I10-P2 / P5, I10-P2 / P4, and I10-P1 / P4 / P5.

[0048] In some embodiments, the hetero-copolymer copolymer comprises a plurality of first propagator blocks and a plurality of second propagator blocks. In a specific embodiment, the number of the first propagator blocks is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more, or any range defined by the endpoint, e.g., 1 to 20, 1 to 18, 1 to 16, 1 to 14, 1 to 12, 1 to 10, 1 to 8, 1 to 6, 1 to 4, 3 to 20, 3 to 18, 3 to 16, 3 to 14, 3 to 12, 3 to 10, 3 to 8, 3 to 6, 3 to 4, 6 to 20, 6 to 18, 6 to 16, 6 to 14, 6 to There are 12, 6 to 10, 6 to 8, 9 to 20, 9 to 18, 9 to 16, 9 to 14, 9 to 12, 12 to 20, 12 to 18, and 12 to 16. In a specific embodiment, the number of second propagator blocks is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more, or any range defined by the endpoint, e.g., 1 to 20, 1 to 18, 1 to 16, 1 to 14, 1 to 12, 1 to 10, 1 to 8, 1 to 6, 1 to 4, 3 to 20, 3 to 18, 3 to 16, 3 to 14, 3 to 12, 3 to 10, 3 to 8, 3 to 6, 3 to 4, 6 to 20, 6 to 18, 6 to 16, 6 to 14, 6 to There are 12, 6 to 10, 6 to 8, 9 to 20, 9 to 18, 9 to 16, 9 to 14, 9 to 12, 12 to 20, 12 to 18, and 12 to 16. In some embodiments, the number of first propagator blocks and / or the number of second propagator blocks may be determined using mass spectrometry, but is not limited thereto.

[0049] Polymer wool comprising the copolymer of the present disclosure

[0050] The polymer pores of the present disclosure comprise a membrane comprising a copolymer of the present disclosure. In some embodiments, the membrane comprises a plurality of copolymers of the present disclosure, which are assembled into a membrane using propagator blocks that couple with one another through hydrophobic interactions. The initiator blocks of each copolymer of the polymer pores extend from the membrane and are exposed to the surrounding environment.

[0051] In some embodiments, the copolymer of the present disclosure comprises at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of the polymer membrane of the polymer wool, or any range defined by the endpoint, e.g., 50% to 99%, 50% to 95%, 50% to 90%, 50% to 85%, 50% to 80%, 50% to 75%, 50% to 70%, 50% to 65%, 50% to 60%, 60% to 99%, 60% to 95%, 60% to 90%, 60% to 85%, 60% to 80%, 60% to 75%, 60% to 70%, 60% to 65%, 70% to 99%, 70% It consists of up to 95%, 70% to 90%, 70% to 85%, 70% to 80%, 50% to 75%, 80% to 99%, 80% to 95%, 80% to 90%, 80% to 85%, 90% to 99%, or 90% to 95%.

[0052] In some embodiments, the membrane comprises at least two different types of copolymers of the present disclosure. In certain embodiments, the membrane comprises a copolymer comprising at least two different types of propagator blocks of the present disclosure. For example, the membrane comprises a copolymer comprising a first propagator block and a second propagator block, wherein the molecular ratio of the first propagator block and the second propagator block in the membrane is 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 15, 20, or 25, or any range defined by the endpoint, e.g., 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2.5, 1 to 2, 1 to 1.5, 2 to 25, 2 to 20, 2 to 15, 2 to 10, 2 to 8, 2 to 6, 2 It is up to 5, 2 to 4, 2 to 3, or 2 to 2.5.

[0053] In some embodiments, the polymerosomes of the present disclosure may be dendritic cell-targeting vaccines (DCTVs) for the specific targeted delivery of a payload to dendritic cells, thereby achieving or improving the immunogenic response of the vaccine.

[0054] Size of the polymer cotton. In some embodiments, the polymer wool of the present disclosure is 0.001, 0.005, 0.01, 0.05, 0.1, 0.15, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5 micrometers, or any range defined by the endpoint, e.g., 0.001 to 5, 0.001 to 4, 0.001 to 3, 0.001 to 2, 0.001 to 1, 0.001 to 0.8, 0.001 to 0.6, 0.001 to 0.4, 0.001 to 0.2, 0.001 to 0.1, 0.001 to 0.05, 0.001 to 0.01, 0.001 to 0.005, 0.05 to 5, 0.05 to 4, 0.05 to 3, 0.05 to 2, 0.05 to 1, 0.05 to 0.8, 0.05 to 0.6, 0.05 to 0.4, 0.05 to 0.2, 0.05 to 0.1, 0.1 to 5, 0.1 to 4, 0.1 to 3, 0.1 to 2, 0.1 to 1, 0.1 to 0.8, 0.1 to 0.6, 0.1 to 0.4, 0.1 to 0.2, 0.5 to 5, 0.5 to 4, 0.5 to 3, It has a diameter of 0.5 to 2, 0.5 to 1, 0.5 to 0.8, 1 to 5, 1 to 4, 1 to 3, or 1 to 2 micrometers. The size of the polymer filaments can be determined using dynamic light scattering (DLS), but is not limited thereto. In some embodiments, the polymer filament of the present disclosure is about 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1, or any range defined by the endpoint, e.g., 0.01 to 1, 0.01 to 0.9, 0.01 to 0.8, 0.01 to 0.7, 0.01 to 0.6, 0.01 to 0.5, 0.01 to 0.4, 0.01 to 0.3, 0.01 to 0.2, 0.01 to 0.1, 0.01 to 0.It has a polyvariance index (PDI) of 05, 0.1 to 1, 0.1 to 0.9, 0.1 to 0.8, 0.1 to 0.7, 0.1 to 0.6, 0.1 to 0.5, 0.1 to 0.4, 0.1 to 0.3, or 0.1 to 0.2.

[0055] Zeta potential and molecular weight. Although I do not want to get bogged down in theory, the zeta potential and molecular weight of polymerosomes can affect their cellular uptake. In some embodiments, the polymer wool of the present disclosure is about -50, -40, -30, -20, -15, -10, -5, 0, +5, +10, +15, +20, +30, +40, or +50, or any range defined by the endpoint, e.g., -50 to +50, -50 to +40, -50 to +30, -50 to +20, -50 to +15, -50 to +10, -50 to +5, -50 to -5, -50 to -10, -50 to -15, -50 to -20, -20 to +50, -20 to +40, -20 to +30, -20 to +20, -20 to +15, -20 to +10, -20 to +5, -20 to -5, -20 to -10, -20 to -15, -15 It includes zeta potentials of up to +50, -15 to +40, -15 to +30, -15 to +20, -15 to +15, -15 to +10, -15 to +5, -15 to -5, -15 to -10, +5 to +50, +5 to +40, +5 to +30, +5 to +20, +5 to +15, or +5 to +10.In some embodiments, the polymer wool of the present disclosure is about 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50 kDa, or any range defined by the endpoint, e.g., 1 to 50 kDa, 1 to 40 kDa, 1 to 30 kDa, 1 to 20 kDa, 1 to 15 kDa, 1 to 10 kDa, 1 to 5 kDa, 2 to 50 kDa, 2 to 40 kDa, 2 to 30 kDa, 2 to 20 kDa, 2 to 15 kDa, 2 to 10 kDa, 2 to 5 kDa, 5 to 50 kDa, 5 to 40 It includes a molecular weight of kDa, 5 to 30 kDa, 5 to 20 kDa, 5 to 15 kDa, 5 to 10 kDa, 8 to 50 kDa, 8 to 45 kDa, 8 to 40 kDa, 8 to 35 kDa, 8 to 30 kDa, 8 to 25 kDa, 8 to 20 kDa, 8 to 15 kDa, 8 to 10 kDa, 12 to 50 kDa, 12 to 45 kDa, 12 to 35 kDa, 12 to 25 kDa, 12 to 15 kDa, 25 to 50 kDa, 25 to 40 kDa, or 25 to 30 kDa.

[0056] Payload. In some embodiments, the membrane of the polymerosome defines an internal space configured to encapsulate or transport a payload. As described herein, “encapsulate a payload,” “encapsulated within an internal space,” or similar descriptions refer to a state in which the payload is retained, enclosed, or surrounded by the membrane of the polymerosome. The payload may be free to move within the internal space or may be covalently or non-covalently attached to the membrane. Encapsulation may be substantial, complete, or partial, and does not exclude the possibility that a portion of the payload may be exposed to the environment outside the polymerosome. In an embodiment of partial encapsulation, at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% of the payload is retained, enclosed, or surrounded by the membrane of the polymerosome. In some embodiments, the payload may be a biomolecule, such as a nucleic acid, compound, polypeptide, protein, glycan head, or a combination thereof.

[0057] In some embodiments, the payload is ribonucleic acid (RNA, e.g., mRNA) or deoxyribonucleic acid (DNA, e.g., double-stranded DNA or single-stranded DNA), which can code for a polypeptide or protein in vivo after being delivered to a target cell using the polymerosomes of the present disclosure. The nucleic acid, e.g., the mRNA molecule used in the present disclosure, may be prepared by in vitro transcription from a reference nucleic acid. In vitro transcription may be performed as described in PCT Patent Publication WO2014 / 152027 filed March 13, 2014 (the full text of which is incorporated by reference).

[0058] In some embodiments, the polypeptide or protein is immunogenic (e.g., antigenic) to the organism to which the polymerosome is administered. In these embodiments, the polymerosome of the disclosure is used to encapsulate and carry an immunogenic protein or a nucleic acid configured to code for an immunogenic protein in vivo, such as an mRNA molecule in an RNA vaccine. The immunogenic protein may be a protein of a pathogen of viral (e.g., SARS-CoV-2, influenza (flu), respiratory syncytial virus (RSV), EBV, DENGUE, VZV, HIV, ZIKA, or NIPAH), bacterial, or fungal origin. In some embodiments, the immunogenic protein may be a spike protein of a virus. In certain embodiments, the spike protein may be of coronavirus (CoV) origin, such as SARS-CoV, MERS-CoV, and SARS-CoV-2. In some embodiments, examples of coronaviruses (CoVs) described herein include, but are not limited to, alpha-SARS-CoV2, beta-SARS-CoV2, gamma-SARS-CoV2, delta-SARS-CoV2, omecro-SARS-CoV2, and variants thereof.

[0059] In some embodiments, the payload is a nucleic acid that may be a polynucleotide having an open reading frame configured to code for a polypeptide or protein in vivo. Such polynucleotides may be modified with a 5' end cap, which is generated during an in vitro transcription reaction using the following chemical RNA cap analogs: 3″-O-Me-m7G(5)ppp(5')G [ARCA cap], G(5)ppp(5')A, G(5)ppp(5')G, m7G(5')ppp(5')A, or m7G(5')ppp(5')G (New England Biolabs, Ipswitch, Massachusetts). The 5'-capping of the modified polynucleotide may be completed after transcription using a vaccinia virus capping enzyme to produce a "cap 0" structure: m7G(5')ppp(5')G (New England Biolabs, Ipswitch, Massachusetts). The Cap 1 structure can be generated using both vaccinia virus capping enzyme and 2'-O methyltransferase to produce m7G(5')ppp(5')G-2'-O-methyl. The Cap 2 structure can be generated from the 2'-O methylation of the third nucleotide from the 5'-end using 2'-O methyltransferase following the Cap 1 structure. The Cap 3 structure can be generated from the 2'-O methylation of the fourth nucleotide from the 5'-end using 2'-O methyltransferase following the Cap 2 structure. The enzymes can be derived from a recombinant source. After transfection into mammalian cells, the modified polynucleotide has stability for 12–18 hours, or for more than 18 hours, e.g., 24, 36, 48, 60, 72 hours, or more than 72 hours.

[0060] In some embodiments, the nucleic acid may be modified. In some embodiments, the nucleic acid may have several (more than one) modifications that are identical or different from one another. In some embodiments, the nucleic acid contains one, two, or more (arbitrarily different) nucleoside or nucleotide modifications in a specific region. In some embodiments, the modified nucleic acid (e.g., modified mRNA polynucleotide) exhibits reduced degradation in a cell or organism compared to the unmodified one. In some embodiments, the modified nucleic acid may each exhibit reduced immunogenicity (e.g., reduced innate response) in an organism.

[0061] In some embodiments, modifications may include chemical modifications. In some embodiments, modifications may be spontaneous, non-spontaneous, or both. Some exemplary modifications useful for the present disclosure include, but are not limited to, modifications of sugars, nucleobases, nucleoside linkages (e.g., linkage phosphates, phosphodiester linkages, or phosphodiester backbones), or combinations thereof. In some embodiments, the nucleic acid (e.g., RNA) used as the payload of the present disclosure may be codon-optimized. For example, the nucleic acid may be modified to increase its G / C content. The G / C content of the nucleic acid may affect its stability. A nucleic acid having increased amounts of guanine (G) and / or cytosine (C) residues may be functionally more stable than one containing large amounts of adenine (A) and thymine (T) or uracil (U) nucleotides. For example, WO2002 / 098443 discloses a pharmaceutical composition containing mRNA stabilized by sequence modification in the translation region. Due to the axiolytic nature of the genetic code, the modification acts by substituting existing codons with those that promote greater RNA stability without altering the resulting amino acids.

[0062] In some embodiments, the nucleic acid may further comprise a sequence encoding a signal peptide. The signal peptide may comprise three regions: (1) an N-terminal region of different lengths containing typically positively charged amino acids, (2) a hydrophobic region, and (3) a short carboxy-terminal peptide region. In eukaryotes, the signal peptide of a nascent precursor protein (pre-protein) directs the ribosome to the endoplasmic reticulum (ER) membrane and initiates the transport of the growing peptide chain across it. The signal peptide typically does not serve as the final destination of the mature protein, but is not limited to this disclosure. The signal peptide is typically cleaved from the precursor protein by an ER-resident signal peptidase. They may remain undecleved and function as membrane anchors. In some embodiments, the signal peptide may be designed to fuse at its C-terminus or N-terminus with a polypeptide or protein encoded by a payload.

[0063] In some embodiments, the payload may be a therapeutic or prophylactic agent for treating or preventing a disease (e.g., cancer or an infectious disease). For example, the payload may be an antiviral agent including, but not limited to, ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine, remedivir (GS-5734), and favipiravir (T-705), interferon, adefovir, tenofovir, acyclovir, brivudine, cidofovir, formivirsen, foscarnet, ganciclovir, amantadine, rimantadine, zanamivir, remedivir, molnupiravir, and paxlovid. In other examples, the payload may be an anticancer agent. In certain embodiments, the payload is a nucleic acid configured to code for a therapeutic or prophylactic agent.

[0064] In some embodiments, the N / P ratio of the polymerosome encapsulating the nucleic acid (positively charged polymeric amine (N = nitrogen) group to negatively charged nucleic acid phosphate (P) group) is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, or 50, or any range defined by the endpoint, e.g., 1 to 50, 1 to 40, 1 to 30, 1 to 20, 1 to 10, 1 to 5, 5 to 50, 5 to 40, 5 to 30, 5 to 20, 5 to 10, 10 to 50, 10 to 40, 10 to 30, 10 to 20, 8 to 40, 8 to 20, 8 to 12, 9 to 50, 9 to 30, or 9 to 15 (included or excluded). In another embodiment, the polymerosome encapsulating the mRNA has a nanoparticle / mRNA (N / P) ratio of about 10 or about 20.

[0065] In some embodiments where the payload of the polymerosome is a nucleic acid configured to code for a polypeptide or protein in a target cell, after absorption by the target cell, the polymerosome comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 copies of the polypeptide or protein, or any range defined by the endpoint, e.g., 1 to 50, 1 to 40, 1 to 30, 1 to 20, 1 to 10, 1 to 5, 2 to 50, 2 to 40, 2 to 30, 2 to 20, 2 to 15, 2 to 10, 2 to 8, 2 to 6, 2 to 5, 2 to 4, 5 to 50, 5 to 40, 5 to 30, 5 to 50, 5 to 5 It is configured to code to 20, 5 to 15, 5 to 10, 5 to 8, 4 to 50, 4 to 45, 4 to 35, 4 to 25, 4 to 15, 4 to 9, 4 to 6, 7 to 50, 7 to 45, 7 to 35, 7 to 25, 7 to 15, or 7 to 9 copies (included or excluded) in vivo. In some embodiments, after absorption by a target cell, the polymerosome is configured to code for a polypeptide or protein in vivo continuously and immediately until the nucleic acid (i.e., payload) is inactivated in vivo.

[0066] Composition / Formulation

[0067] One aspect of the present disclosure relates to a composition (i.e., a formulation) comprising a polymerosome of the present disclosure. The polymerosome of the composition may encapsulate a payload and is configured to deliver the payload to a target area of ​​an organism. The payload may be as described herein, comprising nucleic acids, compounds, peptides, proteins, glycan heads, or combinations thereof. In some embodiments, the payload may be an immunogenic protein, or a nucleic acid configured to code for an immunogenic protein in vivo. In some embodiments, the formulation further comprises pharmaceutically acceptable excipients, ajuvants, or combinations thereof. In certain embodiments, the composition is a pharmaceutical composition or a pharmaceutical formulation.

[0068] In some embodiments, the composition is 0.01, 0.05, 0.1, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 95% (w / w), or any range defined by the endpoint, e.g., 0.01% to 95% (w / w), 0.01% to 90% (w / w), 0.01% to 80% (w / w), 0.01% to 70% (w / w), 0.01% to 60% (w / w), 0.01% to 50% (w / w), 0.01% to 40% (w / w), 0.01% to 30% (w / w), 0.01% to 20% (w / w), 0.01% to 10% (w / w), 0.01% to 5% (w / w), 0.01% to 1% (w / w), 0.01% to 0.1% (w / w), 0.1% to 95% (w / w), 0.1% to 90% (w / w), 0.1% to 80% (w / w), 0.1% to 70% (w / w), 0.1% to 60% (w / w), 0.1% to 50% (w / w), 0.1% to 40% (w / w), 0.1% to 30% (w / w), 0.1% to 20% (w / w), 0.1% to 10% (w / w), 0.1% to 5% (w / w), 0.1% to 1% (w / w), 1% to 95% (w / w), 1% to 90% (w / w), 1% to 80% (w / w), 1% to 70% (w / w), 1% to 60% (w / w), 1% to 50% (w / w), 1% to 40% (w / w), 1% to 30% (w / w), 1% to 20% (w / w), 1% to 10% (w / w), 1% to 5% (w / w), 5% to 95% (w / w), 5% to 90% (w / w), 5% to 80% (w / w), 5% to 70% (w / w), 5% to 60% (w / w), 5% to 50% (w / w), 5% to 40% (w / w), It comprises 5% to 30% (w / w), 5% to 20% (w / w), or 5% to 10% (w / w) (included or excluded) of the polymer wool of the present disclosure that encapsulates or does not encapsulate the payload. The remaining percentage of the composition may be an excipient as described herein.

[0069] In some embodiments, the composition is an mRNA vaccine, wherein the polymerosome encapsulates mRNA configured to code for an immunogenic protein in vivo. The immunogenic protein may be a viral spike protein or other antigenic molecule of a pathogen. In certain embodiments, the composition of the present invention may be a COVID-19 mRNA vaccine.

[0070] An exemplary COVID-19 mRNA vaccine as described herein may be designed based on mRNA technology to remove glycan shields of the coronavirus (e.g., SARS-CoV-2) spike protein to better expose a conserved region of the spike protein. The mRNA vaccine of the coronavirus spike protein has deletions of glycosylation sites within the receptor binding domain (RBD) or subunit 2 (S2) domain to expose highly conserved epitopes and elicits antibody and CD8 T-cell responses with broader protection against alpha, beta, gamma, delta, omicron, and various variants compared to unmodified mRNA. The vaccine may be a low-sugar universal vaccine (LSUV) as described in WO2022 / 221835 (wherein mRNA comprises a sequence selected from sequence identification number: 1-52), WO2022 / 221837A2 (wherein mRNA comprises a sequence selected from sequence identification number: 1-21), and US20200046826A1 (wherein mRNA comprises a sequence selected from sequence identification number: 1-20), the full text of which is incorporated herein by reference.

[0071] In some embodiments, the composition of the present invention is configured to treat or prevent a disease (e.g., cancer). In these embodiments, the payload carried by the polymerosome may be a therapeutic agent, a preventive agent, or a nucleic acid configured to code for a therapeutic agent or a preventive agent in vivo. For example, the composition may be a personalized cancer vaccine (e.g., melanoma), a KRAS vaccine (KRAS-driven), or a checkpoint vaccine (e.g., PD-1, PDL-1 related).

[0072] In some embodiments, the composition of the present invention may be administered together with another composition (e.g., a vaccine or medicine). Examples of the other composition may be, but are not limited to, an influenza (flu) vaccine, an adenovirus vaccine, anthrax vaccine, cholera vaccine, diphtheria vaccine, hepatitis A or B vaccine, HPV vaccine, measles vaccine, mumps vaccine, smallpox vaccine, rotavirus vaccine, tuberculosis vaccine, pneumococcal vaccine, and Haemophilus influenzae type b vaccine.

[0073] Combination composition

[0074] In some embodiments, the composition may be a combo composition (e.g., a combo vaccine) comprising a first polymerosome encapsulating a first payload and a second polymerosome encapsulating a second payload. The first polymerosome and the second polymerosome may be the same as the polymerosome described herein, but differ from one another in terms of the structure or properties of their copolymers. For example, the first polymerosome and the second polymerosome differ in size, the copolymer forming their membrane, the payload encapsulated within the polymerosome, or a combination thereof.

[0075] For example, the first polymerosome comprises a glycan head configured to bind to DC-SIGN, while the second polymerosome comprises a glycan head configured to bind to Siglec-1. In another example, the first polymerosome comprises a glycan configured to target antigen-presenting cells, while the second polymerosome comprises a glycan configured to target cancer cells.

[0076] In some embodiments, the first payload and the second payload are different from each other. For example, the first payload may be a protein or a peptide, while the second payload may be a nucleic acid. In certain embodiments, both the first payload and the second payload may be mRNA molecules but code for different proteins. For example, the first payload may be mRNA configured to code for the spike protein of delta-SARS-CoV2, while the second payload may be mRNA configured to code for the spike protein of omecro-SARS-CoV2.

[0077] Additional components of the composition

[0078] In some embodiments, the composition of the present disclosure may further comprise an ajuvant and / or non-active material, such as pharmaceutically acceptable excipients. In certain embodiments, the ajuvant may be, but is not limited to, C34, gluco-C34, 7DW8-5, C17, C23, C30, α-galactosylceramide (α-GalCer), aluminum salt (e.g., aluminum hydroxide, aluminum phosphate, alum (potassium aluminum sulfate), mixed aluminum salt), squalene, MF59, QS-21, Freund complete ajuvant, Freund incomplete ajuvant, AS03 (GlaxoSmithKline), MF59 (Seqirus), CpG 1018 (Dynavax).

[0079] In certain embodiments, pharmaceutically acceptable excipients may include solvents, dispersion media, diluents, dispersants, suspension aids, surfactants, isotonic agents, thickeners or emulsifiers, preservatives, polymers, peptides, proteins, cells, hyaluronidase, or mixtures thereof. Various excipients for formulating pharmaceutical compositions and techniques for preparing compositions are known in the art (Reference [Remington: The Science and Practice of Pharmacy, 22nd [Refer to Edition, Edited by Allen, Loyd V., Jr, Pharmaceutical Press]). The use of conventional excipient media may be considered to be within the scope of this disclosure, except where any conventional excipient media may be incompatible with a substance or its derivatives by, for example, producing any undesirable biological effect or otherwise interacting in a harmful manner with any other component(s) of the pharmaceutical composition. Formulation of standard pharmaceutically acceptable excipients may be carried out using commercially available methods in the pharmaceutical field (refer to [Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Company, Eastern Pennsylvania, USA]).

[0080] In some embodiments, the composition further comprises a phosphate conjugate. Without being bound by theory, the phosphate conjugate may increase in vivo circulation time and / or increase the targeted delivery of the polymerosomes of the present disclosure. The phosphate conjugate for use in the present disclosure may be prepared using the method described in PCT Publication No. WO2013 / 033438 filed August 30, 2012, or U.S. Publication No. US2013 / 0196948 filed June 23, 2011, the full text of each of which is incorporated herein by reference. As a non-limiting example, the phosphate conjugate may comprise a compound of any formula described in PCT Publication No. WO2013 / 033438 filed August 30, 2012 (the full text of which is incorporated herein by reference).

[0081] In some embodiments, the composition further comprises a conjugate to enhance the delivery of the polymerosomes of the present disclosure. Without being bound by theory, the conjugate selected for use may inhibit the phagocytic clearance of the polymerosomes in the target. In some examples, the conjugate may be the human membrane protein CD47 or a “magnetic” peptide derived therefrom (e.g., the “magnetic” particle described in the literature [Rodriguez et al. (Science 2013, 339, 971-975)], the full text of which is incorporated herein by reference).

[0082] In some embodiments where the payload is an immunogenic agent or a nucleic acid configured to code for an immunogenic agent, the composition further comprises an immunostimulator that enhances the immune response induced by the immunogenic agent. As a non-limiting example, the composition may comprise a Th1 immunostimulator capable of enhancing the Th1-based response of the immune system (see PCT Publication No. WO2010 / 123569 and U.S. Publication No. 2011 / 0223201, the full text of which is incorporated herein by reference).

[0083] In some embodiments, the composition does not contain viral components (e.g., viral capsid, viral enzyme, or other viral proteins, e.g., those required for virus-based replication), nor is it packaged within, encapsulated within, linked to, or otherwise associated with a virus or viral particle.

[0084] Polymer cotton manufacturing kit

[0085] One aspect of the present disclosure relates to a kit for manufacturing a polymer some of the present disclosure. The kit comprises a first reagent and a second reagent, wherein the first reagent comprises an initiator comprising a glycan head and an initiator linking moiety, and the second reagent comprises a propagator comprising a functional moiety and a propagator linking moiety, wherein the functional moiety comprises a guanidine group, a zwitterion group, a diethylenetriamine, or a combination thereof; wherein the initiator linking moiety is configured to be coupled to the propagator linking moiety through a link comprising a disulfide bond.

[0086] In some embodiments, the initiator linking moiety is configured to be coupled with the propagator linking moiety to form a link of the copolymer of the present disclosure. In some embodiments, the initiator linking moiety and the propagator linking moiety are independently thiol groups or dithiolan groups.

[0087] In some embodiments, the kit further comprises a reagent comprising a payload to be encapsulated by a polymer swab prepared by using the kit of the present disclosure. In certain embodiments, the payload may be as described herein.

[0088] Initiator

[0089] The initiator comprises a glycan head and an initiator linkage moiety. In some embodiments, the glycan head is described in the initiator block of the copolymer of the present disclosure.

[0090] In some embodiments, the initiator molecule further comprises an initiator spacer as described herein in the copolymer of the present disclosure. In certain embodiments, the initiator spacer comprises a saturated carbon moiety, a polyethylene glycol (PEG) moiety, or a combination thereof.

[0091] In some embodiments, the initiator is selected from the group consisting of:

[0092]

[0093]

[0094] spreader

[0095] The propagator comprises a functional moiety and a propagator linkage moiety, wherein the functional moiety comprises a guanidine group, a zwitterion group, a diethylenetriamine, or a combination thereof. In some embodiments, the functional moiety of the propagator molecule is as described in the propagator block of the copolymer of the present disclosure.

[0096] In some embodiments, the propagator further comprises a propagator spacer as described herein in the copolymer of the present disclosure. In certain embodiments, the propagator spacer comprises a saturated carbon moiety, a polyethylene glycol (PEG) moiety, or a combination thereof.

[0097] In some embodiments, the second reagent comprises two types of propagators, each having a different structure or the desired properties provided by them. For example, the second reagent may comprise a first propagator and a second propagator, each independently comprising a functional moiety comprising a guanidine group, a zwitterion group, diethylenetriamine, or a combination thereof. In certain embodiments, the first propagator comprises a guanidine group, and the second propagator comprises a zwitterion group. In other embodiments, the first propagator comprises a guanidine group, and the second propagator comprises diethylenetriamine.

[0098] In some other embodiments, the kit further comprises a third reagent comprising a propagator that differs from the propagator of the second reagent in structure or the desired properties provided by it. For example, the propagator of the second reagent is a first propagator molecule, and the third reagent comprises a second propagator. The first propagator and the second propagator may independently comprise a functional moiety comprising a guanidine group, a zwitterion group, diethylenetriamine, or a combination thereof. In certain embodiments, the first propagator comprises a guanidine group, and the second propagator comprises a zwitterion group. In other embodiments, the first propagator comprises a guanidine group, and the second propagator comprises diethylenetriamine.

[0099] In some embodiments, the propagator is selected from the group consisting of:

[0100]

[0101] Packaging

[0102] All components of the kit of the present disclosure may each be packaged in a physical container. In some embodiments, the first reagent and the second reagent are contained in the same container; that is, they are in a package ready for immediate use. In some other embodiments, the first reagent and the second reagent are contained in separate containers so that the user can decide whether and when to mix them.

[0103] How to use

[0104] One aspect of the present disclosure relates to a method of using the polymerosomes of the present disclosure. In particular, the method is performed to obtain a desired effect, such as the targeted delivery of a payload, the prevention or treatment of a disease, or the boosting of an adaptive immune response in a subject. In some embodiments, the subject may be, but is not limited to, an animal or human in which the payload is designed to exhibit its efficacy, or in which the treatment or prevention of a disease is required, or in which the adaptive immune response is required to be boosted.

[0105] Method of delivering a target payload to an object

[0106] In some embodiments, a method for targeted delivery of a payload to a subject is provided, comprising administering an effective amount of the polymerosome of the present disclosure to the subject. In some embodiments, a method for targeted delivery of a payload to a subject is provided, comprising administering an effective amount of the pharmaceutical formulation of the present disclosure to the subject. The polymerosome and the payload are as described herein, and the polymerosome encapsulates the payload within an internal space defined by the membrane of the polymerosome.

[0107] Although I do not wish to be bound by any theory, targeted delivery is achieved by an initiator block of a copolymer forming a polymerosome. In particular, the initiator block provides a targeted binding affinity / specificity that targets a desired region of the target through its glycan head.

[0108] Methods to prevent or treat diseases in subjects

[0109] In some embodiments, a method for preventing or treating a disease in a subject is provided, comprising administering an effective amount of the polymerosomes of the present disclosure to the subject. The polymerosomes of the method encapsulate a payload within an internal space defined by the membrane of the polymerosomes, and the payload is a therapeutic agent configured to prevent and / or treat the disease or induces a therapeutic agent.

[0110] While not wishing to be bound by any theory, the polymerosomes of the present disclosure provide targeted delivery through the glycan heads of their copolymers. Thus, by using the polymerosomes of the present disclosure to deliver a payload, the efficacy of the payload can be achieved more effectively. For example, in an embodiment comprising a structure in which the glycan head specifically binds to a DC-SIGN on a dendritic cell, an antigenic or immunogenic payload can be effectively delivered to the dendritic cell to induce an immune response to prevent the disease of interest. This strategy is beneficial for delivering antigens of vaccines or nucleic acids encoding antigens. Some other examples include having glycan heads designed to target cancer cells so that an antitumor agent can be effectively delivered into the tumor microenvironment. This strategy can increase the efficacy of the antitumor agent and reduce the side effects of the treatment.

[0111] In some embodiments, the disease is characterized by dysfunctional or abnormal protein or polypeptide activity. For example, the disease is selected from the group consisting of rare diseases, infectious diseases, cancer and proliferative diseases, genetic diseases (e.g., cystic fibrosis), autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases, and metabolic diseases.

[0112] In some embodiments, the disease may be cancer or an infectious disease. In certain embodiments, the disease may be a virus-associated infection including, but not limited to, human parainfluenza virus 3, respiratory syncytial virus (RSV), cytomegalovirus (CMV), human metapneumovirus (hMPV), or SARS-CoV-2 (COVID-19) associated infections.

[0113] How to boost the adaptive immune response

[0114] In some embodiments, a method for boosting an adaptive immune response is provided, comprising administering an effective amount of the polymerosomes of the present disclosure to a subject. The polymerosomes of the method encapsulate a payload within an internal space defined by the membrane of the polymerosomes, and the payload is a therapeutic agent configured to induce an adaptive immune response in the subject or induces a therapeutic agent.

[0115] While not wishing to be bound by any theory, the polymerosome of the present disclosure provides targeted delivery to immune cells through the glycan heads of its copolymer. In some embodiments, the glycan heads comprise structures that bind to antigen-presenting cells with desired specificity or affinity. For example, the glycan heads comprise structures that specifically bind to DC-SIGN on dendritic cells, so that the polymerosome can specifically deliver an immunogenic payload to dendritic cells to facilitate the initiation of an adaptive immune response.

[0116] In some embodiments, the boosted adaptive immune response is for a disease that includes, but is not limited to, cancer or an infectious disease. The infectious disease may be a virus-associated infection, for example, human parainfluenza virus 3, respiratory syncytial virus (RSV), cytomegalovirus (CMV), human metapneumovirus (hMPV), or SARS-CoV-2 (COVID-19) associated infection, but is not limited to.

[0117] administration

[0118] In connection with the method of the present disclosure, in some embodiments, the subject is administered a single dose of the polymer som or formulation of the present disclosure, with or without encapsulating the payload. Also, in some embodiments, the subject is subjected to an initial dose and subsequently at least one booster dose, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more follow-up doses of polymer wool for about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 weeks, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months, or any range defined by the endpoint, for example, 1 to 7 days, 1 to 5 days, 1 to 3 days, 1 to 10 weeks, 1 to Each dose is administered at intervals of 8 weeks, 1 to 6 weeks, 1 to 4 weeks, 1 to 2 weeks, 1 to 12 months, 1 to 8 months, 1 to 6 months, 1 to 4 months, 1 to 2 months, or 6 to 12 months (included or excluded). In certain embodiments, the polymerosomes of the present disclosure encapsulating the payload are administered twice at the same or different doses, and the two administrations are separated by 1 day, 3 days, 5 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 1 year, 1 to 5 days, 1 to 2 weeks, 1 to 3 months, 1 to 6 months, 1 month to 1 year, 3 months to 1 year, or 6 months to 1 year.

[0119] Route of administration. Polymerosomes or compositions as described herein may be administered by any route. Suitable routes include, but are not limited to, oral, nasal, mucosal, submucosal, intravenous, intramuscular, intraperitoneal, subcutaneous, intradermal, transdermal, and buccal routes. Some actual topical applications include, but are not limited to, drops, sprays, aerosols, gels, or ointments to the mucosal epithelium of the eyes, nose, mouth, anus, or vagina. Other possible routes of administration are by application of sprays, aerosols, or powders by inhalation through the respiratory tract.

[0120] Administration of an effective amount. The effective amount described herein refers to an amount sufficient to provide the desired effect. In embodiments where the purpose of administering the polymerosomes of this disclosure is to treat a disease, the effective amount refers to a therapeutic effective amount, whereas in some other embodiments where the purpose is to prevent a disease, the effective amount refers to a preventive effective amount.

[0121] In some other embodiments where the purpose of administering polymerosomes containing a payload is to boost an adaptive immune response, the effective amount may be determined as an amount sufficient to induce an antigen-specific immune response in the subject to which the polymerosomes and payload are administered. The antigen-specific immune response may be characterized by measuring the titers of anti-antigenic polypeptides (i.e., the payload or products of the payload) produced in the subject to which the polymerosomes and payload are administered. In some embodiments, the measurement may be performed using an enzyme-linked immunosorbent assay (ELISA).

[0122] In some embodiments, antibody titers are used to assess whether a subject has an infection or to determine whether immunization is required. In some embodiments, antibody titers are used to determine the intensity of an autoimmune response and / or to determine whether booster immunization is required or if immunization has been boosted and / or to determine whether a previous vaccine was effective and / or to identify any recent or previous infection.

[0123] The effective amount of the method of the present disclosure may be determined based on various factors, including but not limited to the subject's condition (age, sex, species, body weight, health status, etc.), the progression of the disease to be treated, the route of administration, the dosage and administration interval, and the nature of the payload. Regarding the nature of the payload, for example, in an embodiment where the polymerosomes of the present disclosure are used to carry mRNA as in an mRNA vaccine, the effective amount may be determined based on the effective amount of mRNA required to induce a sufficient immune response in the subject. Accordingly, in some embodiments where the payload is mRNA, the effective amount of the method of the present disclosure is about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 micrograms (μg or ug), or any range defined by the endpoint, e.g., 5 micrograms to 1000 micrograms, 5 micrograms to 900 micrograms, 5 micrograms to 800 micrograms, 5 micrograms to 700 micrograms, 5 micrograms to 600 micrograms, 5 micrograms to 500 micrograms, 5 micrograms to 400 micrograms, 5 micrograms to 300 micrograms, 5 micrograms to 200 micrograms, 5 micrograms to 175 micrograms, 5 micrograms to 150 micrograms, 5 micrograms to 125 micrograms, 5 micrograms to 100 micrograms, 5 micrograms to 90 micrograms, 5 micrograms to 80 micrograms, 5 micrograms to 70 micrograms, 5 micrograms to 60 micrograms, 5 micrograms to 50 micrograms, 5 micrograms to 40 micrograms,5 micrograms to 30 micrograms, 5 micrograms to 20 micrograms, 5 micrograms to 10 micrograms, 10 micrograms to 1000 micrograms, 10 micrograms to 900 micrograms, 10 micrograms to 800 micrograms, 10 micrograms to 700 micrograms, 10 micrograms to 600 micrograms, 10 micrograms to 500 micrograms, 10 micrograms to 400 micrograms, 10 micrograms to 300 micrograms, 10 micrograms to 200 micrograms, 10 micrograms to 175 micrograms, 10 micrograms to 150 micrograms, 10 micrograms to 125 micrograms, 10 micrograms to 100 micrograms, 10 micrograms to 90 micrograms, 10 micrograms to 80 micrograms, 10 micrograms to 70 micrograms, 10 micrograms to 60 micrograms, 10 micrograms to 50 micrograms, 10 micrograms to 40 micrograms, 10 micrograms to 30 micrograms, 10 micrograms to 20 micrograms, 50 micrograms to 1000 micrograms, 50 micrograms to 900 micrograms, 50 micrograms to 800 micrograms, 50 micrograms to 700 micrograms, 50 micrograms to 600 micrograms, 50 micrograms to 500 micrograms, 50 micrograms to 400 micrograms, 50 micrograms to 300 micrograms, 50 micrograms to 200 micrograms, 50 micrograms to 175 micrograms, 50 micrograms to 150 micrograms, 50 micrograms to 125 micrograms, 50 micrograms to 100 micrograms, 50 micrograms to 90 micrograms, 50 micrograms to 80 micrograms, 50 micrograms to 70 micrograms,or 50 micrograms to 60 micrograms, 100 micrograms to 1000 micrograms, 100 micrograms to 900 micrograms, 100 micrograms to 800 micrograms, 100 micrograms to 700 micrograms, 100 micrograms to 600 micrograms, 100 micrograms to 500 micrograms, 100 micrograms to 400 micrograms, 100 micrograms to 300 micrograms, 100 micrograms to 200 micrograms, 100 micrograms to 175 micrograms, 100 micrograms to 150 micrograms, 300 micrograms to 1000 micrograms, 300 micrograms to 900 micrograms, 300 micrograms to 800 micrograms, 300 micrograms to 700 micrograms, 300 micrograms to 600 micrograms, 300 micrograms to 500 micrograms, 300 to 400 micrograms, 500 to 1000 micrograms, 500 to 900 micrograms, 500 to 800 micrograms, 500 to 700 micrograms, 500 to 600 micrograms, 600 to 800 micrograms, or 700 to 900 micrograms (included or excluded).

[0124] Nevertheless, considering the targeted delivery provided by the polymer pores of the present disclosure, it can be expected that the effective amount required in the method of the present disclosure may be lower than the effective amount required in other non-targeted delivery methods. For example, the effective amount required in the method of the present disclosure is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 95, or 99% of the effective amount required in other non-targeted delivery methods, or any range defined by the endpoint, e.g., 1 to 99%, 1 to 95%, 1 to 90%, 1 to 80%, 1 to 70%, 1 to 60%, 1 to 50%, 1 to 40%, 1 to 30%, 1 to 20%, 1 to 10%, 1 to 5%, 5 to 99%, 5 to 95%, 5 to 90%, 5 to 80%, 5 to 70%, 5 to 60%, 5 to 50%, 5 to 40%, 5 to 30%, 5 to 20%, 5 to 10%, 10 to 90%, 10 to 80%, 10 to 70%, 10 to 60%, 10 to 50%, 10 to 40%, 10 to 30%, 10 to 20%, 30 to 99%, 30 to 95%, 30 to 90%, 30 to 80%, 30 to 70%, 30 to 60%, 30 to 50%, 30 to 40%, 50 to 99%, 50 to 95%, 50 to 90%, 50 to 80%, 50 to It may be lower by 70%, 50 to 60%, 70 to 99%, 70 to 95%, 70 to 90%, 70 to 80%, 80 to 99%, 80 to 95%, 80 to 90%, 90 to 99%, or 95 to 99% (included or excluded).

[0125] Furthermore, in some embodiments in which the polymerosomes of the present disclosure are used to deliver an antigenic agent or a nucleic acid encoding an antigenic agent to induce an immune response to an antigenic agent, the titer of the antibody induced by the present disclosure is increased by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 log compared to the titer of the antibody induced by a non-targeted delivery method, or any range defined by the endpoint, e.g., 1 to 10 log, 1 to 8 log, 1 to 6 log, 1 to 4 log, 2 to 9 log, 2 to 7 log, 2 to 5 log, 3 to 10 log, 3 to 8 log, 3 to 5 log, or 4 to 6 log (included or excluded).

[0126] In some other embodiments, where the polymerosomes of the present disclosure are used to induce an immune response to an antigenic agent by delivering an antigenic agent or a nucleic acid encoding an antigenic agent, the antibody titer to the antigenic agent induced by the present disclosure is 0.1, 0.2, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times compared to a non-targeted delivery method, or any range defined by the endpoint, e.g., 0.1 to 10, 0.1 to 9, 0.1 to 8, 0.1 to 7, 0.1 to 6, 0.1 to 5, 0.1 to 4, 0.1 to 3, 0.1 to 2, 0.1 to 1, 0.1 to 0.5, 0.5 to 10, 0.5 to 9, 0.5 to 8, 0.5 to 7, 0.5 to 6, 0.5 to 5, 0.5 to 4, 0.5 to 3, 0.5 to 2, 0.5 to 1, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, 3 to 10, 3 to 9, 3 to 8, 3 to 7, 3 to 6, 3 to 5, 3 to 4, 5 to 10, 5 to 9, 5 to 8, 5 to 7, 5 to 6, 7 to 10, 7 to 9, 7 to 8, or 8 to 10 times (included or excluded) higher.

[0127] Also, in some embodiments in which the polymerosomes of the present disclosure are used to deliver an antigenic agent or a nucleic acid encoding an antigenic agent to induce an immune response to an antigenic agent, the immune response is induced 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or 20 days earlier than the immune response induced by the non-targeted delivery method, or any range defined by the endpoint, e.g., 1 to 20, 1 to 18, 1 to 14, 1 to 10, 1 to 6, 2 to 20, 2 to 18, 2 to 14, 2 to 10, 2 to 6, 5 to 20, 5 to 18, 5 to 14, or 5 to 10 days (inclusive or excluded).

[0128] In some embodiments, in the method of the present disclosure, the polymer some as described herein is administered at least once a day at a dosage level sufficient to deliver a payload of about 0.0001 mg / kg to about 100 mg / kg, about 0.001 mg / kg to about 0.05 mg / kg, about 0.005 mg / kg to about 0.05 mg / kg, about 0.001 mg / kg to about 0.005 mg / kg, about 0.05 mg / kg to about 0.5 mg / kg, about 0.01 mg / kg to about 50 mg / kg, about 0.1 mg / kg to about 40 mg / kg, about 0.5 mg / kg to about 30 mg / kg, about 0.01 mg / kg to about 10 mg / kg, about 0.1 mg / kg to about 10 mg / kg, or about 1 mg / kg to about 25 mg / kg per day per subject body weight. It is administered to obtain the desired in vivo effect.

[0129] definition

[0130] Unless otherwise specifically defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure pertains. Unless otherwise noted, the technology used or considered herein is a standard methodology widely known to those skilled in the art. Practice of this disclosure will, unless otherwise indicated, utilize the ordinary technology of microbiology, tissue culture, molecular biology, chemistry, biochemistry, and recombinant DNA technology within the art of the relevant field. Materials, methods, and examples are merely illustrative and are not limiting. The following are presented as examples and are not intended to limit the scope of this disclosure.

[0131] Numbers expressing the amount, characteristics, such as molecular weight, reaction conditions, and results of a component used to describe and claim specific embodiments of the present disclosure should be understood as being modified by the term “about” in some cases. A person skilled in the art will understand the meaning of the term “about” in relation to the value it limits. The numbers presented in some embodiments of the present disclosure may contain specific errors resulting from the standard deviation in each of their test measurements. For example, as used herein, the term “about” refers to a measurable value, such as a quantity, duration of time, etc., and is intended to encompass a variation of ±20%, ±10%, ±5%, ±1%, or ±0.1% from the specified value, as such variation is appropriate.

[0132] As used herein, "substantially" means sufficient to function for the intended purpose. Accordingly, the term "substantially" allows for minor, insignificant variations from the absolute or perfect condition, dimensions, measurements, results, etc., as expected by a person skilled in the art, but does not perceptibly affect overall performance. When used in relation to numerical values, or parameters or features expressed as numerical values, "substantially" means within 10 percent.

[0133] As used herein, “treat,” “treat,” and “treating” refer to an approach to obtain a beneficial or desired result, e.g., a clinical result. For the purposes of this disclosure, a beneficial or desired result may include inhibiting or preventing the onset or progression of an infection or disease; improving the symptoms of an infection or disease or reducing its occurrence; or a combination thereof.

[0134] As used herein, “preventive” and “preventive” are used interchangeably with “prevention” and may mean the complete prevention of an infection or the prevention of the occurrence of symptoms of such infection, the delay of the onset of the disease or its symptoms; or the reduction of the severity of a subsequently occurring infection or its symptoms.

[0135] As used herein, "glycan" refers to polysaccharides, oligosaccharides, or monosaccharides. Glycans may be monomers or polymers of sugar residues and may be linear or branched. Glycans may include natural sugar residues (e.g., glucose, N-acetylglucosamine, N-acetylneuraminic acid, galactose, mannose, fucose, hexose, arabinose, ribose, xylose, etc.) and / or modified sugars (e.g., 2'-fluororibose, 2'-deoxyribose, phosphomannose, 6'-sulfo N-acetylglucosamine, etc.).

[0136] Examples

[0137] Example 1: Synthesis of an exemplary polymer wool

[0138] Chemicals and Methods

[0139] For chemical synthesis, all starting materials and commercially available reagents were purchased from Sigma-Aldrich and used as provided unless otherwise indicated. All reactions were carried out in oven-dried glassware under a nitrogen atmosphere using a dry solvent. 1 H and 13 The 1C NMR spectrum was recorded on a Bruker AV-600 spectrometer, and the solvent used was referenced ( 1 H and 13 For C, CDCl3 at δ 7.24 and 77.23, CD3OD at δ 3.31 and 49.2, D2O at δ 4.80, and DMSO-d6 at δ 2.5 and 39.51, respectively. Chemical shift (δ) is reported in ppm using the following definitions: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quadruplet, m = multiplet), integral, and coupling constant (J), where J is reported in Hz. High-resolution mass spectra were recorded under ESI-TOF mass spectrometry conditions. Silica gel (E, Merck) was used for flash chromatography. The IMPACT™ system (Intein-mediated purification using affinity chitin-binding tags) was purchased from New England Biolabs. His-tag purification resin was purchased from Roche. A Hytlab IMAC column (5 mL) was purchased from GE Healthcare Life Sciences. Gel permeation chromatography (GPC) equipped with an Ultimate 3000 liquid chromatograph coupled with a 101 refractive index detector and a Shodex column was used at 30°C for 1 mL min -1The polymer product was analyzed using THF as the eluent at a given flow rate. Correction was based on the narrow linear poly(styrene) SHODEX standard (SM-105). The Mw and dispersion of the polymer product were calculated using DIONEX Chromeleon software. Transmission electron microscopy (TEM) images were obtained using an FEI Technai G2 F20 S-Twin.

[0140] The chemical substances and methods described herein apply to all embodiments described in this disclosure.

[0141] Manufacture of an exemplary propagator of the present disclosure

[0142] Five exemplary propagators, propagators P1, P2, P3, P4, and P5, are described herein. Methods for preparing propagators P1 (Compound 2), P2 (Compound 3), and P4 (Compound 8) are exemplified in Reaction Scheme 1 below. Propagator P3 (Compound 11) was prepared according to Reaction Scheme 2 below. Propagator P5 (Compound 14) was prepared according to Reaction Scheme 3 below. The compounds obtained at each step of the reaction scheme were identified by NMR. Further details and data are described below.

[0143] Reaction Equation 1

[0144]

[0145] Reaction Equation 2

[0146]

[0147] Reaction Equation 3

[0148]

[0149] Compound 1.

[0150]

[0151] Compound 1 was synthesized and characterized based on published procedures. 1H NMR (600 MHz, CDCl3): δ 5.92 (br, 1H), 3.60–3.57 (m, 1H), 3.29 (dt, J = 11.2 Hz, 2H), 3.21–3.10 (m, 2H), 2.86–2.79 (m, 2H), 2.55–2.31 (m, 1H), 2.21 (t, 2H, J = 7.4 Hz), 1.90–1.85 (m, 1H), 1.77–1.41 (m, 8H). Synthesis was performed according to the literature [Jiaqi Fu et al., Journal of the American Chemical Society 2015 137 (37), 12153-12160], the full text of which is incorporated herein by reference.

[0152] Compound 2.

[0153]

[0154] Compound 2 was synthesized and characterized based on a disclosed procedure. 1 ¹H NMR (600 MHz, MeOD): δ 3.98 (s, 1H), 3.61-3.39 (m, 1H), 3.30-3.22 (m, 4H), 3.22-2.88 (m, 2H), 2.56-2.30 (m, 1H), 2.21 (t, J = 7.4 Hz, 2H), 1.98-1.72 (m, 1H), 1.79-1.30 (m, 6H). Synthesis was performed according to the literature [Jiaqi Fu et al., Journal of the American Chemical Society 2015 137 (37), 12153-12160], the full text of which is incorporated herein by reference.

[0155] Compound 3.

[0156]

[0157] Compound 3 was synthesized and characterized based on a disclosed procedure. 1H NMR (600 MHz, CDCl3): δ 3.61 - 3.56 (m, 1H), 3.41 - 3.34 (m, 1H), 3.31 - 3.16 (m, 8H), 3.14 - 3.06 (m, 2H), 2.54 - 2.40 (m, 1H), 2.08 (t, J = 7.4 Hz, 2H), 1.95 - 1.86 (m, 1H), 1.69 (s, 1H), 1.55 (m, 3H), 1.47 - 1.31 (m, 2H). The synthesis was described in Guo, J. et al., Rational Design of Poly(disulfide)s as a Universal Platform for Delivery of CRISPR-Cas9 Machineries toward Therapeutic Genome Editing. It was performed in accordance with ACS Central Science 2021, 7, 990-1000] (the full text of which is incorporated herein by reference).

[0158] Compound 4.

[0159]

[0160] Compound 4 was synthesized and characterized according to the published protocol. 1 ¹H NMR (600 MHz, DMSO-d6): δ 7.44-7.12 (m, 5H), 5.02 (s, 2H), 3.62-3.41 (m, 4H), 3.35 (t, 1H, J = 7.2 Hz), 2.98 (d, 2H, J = 5.9 Hz), 1.79-1.03 (m, 6H). Synthesis was performed according to the literature [Jiaqi Fu et al., Journal of the American Chemical Society 2015 137 (37), 12153-12160], the full text of which is incorporated herein by reference.

[0161] Compound 5.

[0162]

[0163] Compound 5 was synthesized and characterized according to the published protocol.1 ¹H NMR (600 MHz, CDCl3): δ 11.52 (br, 1H), 8.62 (s, 1H), 3.45 (q, J = 4.00 Hz, 2H), 2.86 (t, J = 4.00 Hz, 2H), 1.49 (s, 9H), 1.48 (s, 9H). Synthesis was performed according to the literature [Kuppusamy, R. et al., Design and synthesis of short amphiphilic cationic peptidomimetics based on biphenyl backbone as antibacterial agents. Eur. J. Med. Chem. 2018, 143, 1702-1722] (the full text of which is incorporated herein by reference).

[0164] Compound 6.

[0165]

[0166] A solution of 4 (0.126 mmol) in 1 mL of DMF was preactivated with EDC (0.506 mmol), HOBt (0.506 mmol), and trimethylamine (0.57 mmol) under nitrogen for 30 minutes. Subsequently, 5 (0.506 mmol) in 1 mL of DMF was added to the solution, and the resulting solution was stirred at room temperature for 12 hours. The mixture was concentrated and dried under vacuum, then diluted with ethyl acetate. The organic layer was washed three times with H2O, dried over MgSO4, filtered, and concentrated. The crude product was purified by column chromatography (MeOH / DCM 1:20) on silica gel to obtain 6 (134 mg, 74%). 1H NMR (600 MHz, CDCl3): δ 11.45-11.33 (m, 3H), 8.53-8.45 (m, 3H), 8.35 (t, J = 4.9 Hz, 2H), 7.33-7.25 (m, 5H), 5.04 (s, 2H), 3.59-3.19 (m, 16H), 3.15-3.12 (q, J = 6.0 Hz, 2H), 3.06-3.04 (t, J = 6.9 Hz, 1H), 1.77-1.71 (m, 1H), 1.55-1.32 (m, 59H). HRMS (ESI) Calculated C 57 H 97 N 14 O 17 [M+H] + m / z 1249.7156; measured: 1249.7166.

[0167] Compound 7.

[0168]

[0169] Palladium charcoal (Pd / C, 10% Pd content, 13 mg) was added to a solution of 6 (0.12 mmol) in 2 mL of MeOH. The mixture was stirred at room temperature for 6 hours under a hydrogen gas atmosphere. The solution was filtered through a Celite pad. The residue was concentrated and dried under vacuum, and the resulting residue was dissolved in 2 mL of DCM. Lipoic acid (0.152 mmol), EDCI (0.304 mmol), HOBt (0.304 mmol), and TEA (0.304 mmol) were added to the mixture, and then stirred at room temperature for 2 hours. The mixture was concentrated and dried under vacuum, and then diluted with ethyl acetate. The organic layer was washed three times with H2O, dried over MgSO4, filtered, and concentrated. The crude product was purified by column chromatography (MeOH / DCM 1:50) on silica gel to obtain 7 (94 mg, 82%). 1H NMR (600 MHz, CDCl3): δ 11.48-11.30 (m, 3H), 8.57-8.46 (m, 3H), 8.40 (t, J = 5.2 Hz, 2H), 8.15-8.12 (m, 1H), 6.22-6.18 (m, 1H), 3.60-3.34 (m, 16H), 3.28-3.04 (m, 7H), 2.48-2.38 (m, 1H), 2.17-2.14 (t, J = 7.4 Hz, 2H), 1.92-1.71 (m, 11H), 1.71-1.59 (m, 4H), 1.57-1.34 (m, 64H). HRMS (ESI) Calculated Value C 57 H 103 N 14 O 16 S2[M+H] + m / z 1303.7118; measured: 1303.7129.

[0170] Compound 8.

[0171]

[0172] Compound 7 (0.08 mmol) was added to a solution of 4 M HCl (0.5 mL) in 1,4-dioxane (0.5 mL), and the mixture was stirred at room temperature for 12 hours. Afterward, the solution was removed and dried under vacuum to obtain 8 (24 mg, 89%). 1 H NMR (600 MHz, DO): δ 3.60-3.40 (m, 3H), 3.4-3.16 (m, 16H), 3.02 (s, 2H), 2.76 (s, 2H), 2.20-2.03 (m, 2H), 1.98-1.76 (m, 2H), 1.62-1.16 (m, 11H). 1313C NMR (150 MHz, D2O): δ 176.61, 175.62, 173.68, 172.92, 156.88 (x3), 66.01, 65.73, 56.57, 55.36, 55.24, 40.40 (x2), 40.27, 38.69, 37.99 (x3), 37.82, 35.44, 33.57, 28.66, 28.18, 27.73, 24.99, 22.71. HRMS (ESI) calculated value C 27 H 55 N 14 O4S2[M+H] + m / z 703.3967; measured: 703.3995.

[0173] Compound 9.

[0174]

[0175] A solution of lipoic acid (2.5 mmol) in DMF (3 mL) was preactivated with EDCI (3 mmol), HOBt (3 mmol), and trimethylamine (3 mmol) under nitrogen for 30 minutes. Subsequently, lysine (1 mmol) in DMF (3 mL) was added to the solution, and the resulting solution was stirred at room temperature for 2 hours. The mixture was concentrated and dried under vacuum, then diluted with ethyl acetate. The organic layer was washed three times with H2O, dried over MgSO4, filtered, and concentrated. The crude product was purified by column chromatography (MeOH / DCM 1:20) on silica gel to obtain 9 (230 mg, 90%). 1H NMR (600 MHz, MeOD): δ 4.37-4.32 (dd, J = 4.6, 9.2 Hz, 1H), 3.63-3.57 (qui, J =6.8 Hz, 2H), 3.22-3.17 (m, 4H), 3.14-3.09 (m, 2H), 2.51-2.45 (m, 2H), 2.29 (t, J = 7.0 Hz, 2H), 2.21 (t, J = 7.0 Hz, 2H), 1.95-1.86 (m, 3H), 1.79-1.62 (m, 9H), 1.60-1.40 (m, 8H). HRMS (ESI) Calculated C 57 H 97 N 14 O 17 [M+H] + m / z 1249.7156; measured: 1249.7166.

[0176] Compound 10.

[0177]

[0178] A solution of 9 (0.141 mmol) in 1 mL of DMF was preactivated with EDC (0.211 mmol), HOBt (0.211 mmol), and trimethylamine (0.282 mmol) under nitrogen for 30 minutes. Subsequently, 5 (0.183 mmol) in 1 mL of DMF was added to the solution, and the resulting solution was stirred at room temperature for 2 hours. The mixture was concentrated and dried under vacuum, then diluted with ethyl acetate. The organic layer was washed three times with H2O, dried over MgSO4, filtered, and concentrated. The crude product was purified by column chromatography (MeOH / DCM 1:20) on silica gel to obtain 10 (92 mg, 84%). 1H NMR (600 MHz, CDCl3): δ 11.39 (s, 1H), 8.58 (t, J = 6.0 Hz, 1H), 7.98 (t, J = 4.6 Hz, 1H), 6.41 (d, J = 7.4 Hz, 1H), 5.79-5.74, (m, 1H), 4.37 (q, J = 7.5 Hz, 1H), 3.57-3.48 (m, 4H), 3.44-3.35 (m, 2H), 3.26-3.12 (m, 4H), 3.11-3.05 (m, 2H), 2.46-2.39 (m, 2H), 2.18 (t, J = 7.4 Hz, 2H), 2.13 (t, J = 7.4 Hz, 2H), 1.91-1.84 (m, 2H), 1.82-1.75 (m, 1H), 1.71-1.57 (m, 9H), 1.54-1.35 (m, 20H), 1.33-1.25 (m, 2H). 13 C NMR (150 MHz, CDCl3): δ 172.91, 172.55, 171.72, 162.87, 157.42, 153.03, 83.72, 79.97, 56.46, 56.44, 52.78, 41.19, 40.27, 40.26, 40.20, 38.96, 38.48 (x2), 36.48, 36.37, 36.30, 34.64, 34.61, 32.60, 29.18, 28.95, 28.88, 28.29 (x2), 28.05 (x2), 25.46, 25.36, 25.32, 22.29. HRMS (ESI) 계산치 C 35 H 63 N6O7S4[M+H] + m / z 807.3641; 실측치: 807.3655.

[0179] 화합물 11.

[0180]

[0181] Compound 10 (0.1 mmol) was added to a solution of 4 M HCl (0.5 mL) in 1,4-dioxane (0.5 mL), and the mixture was stirred at room temperature for 12 hours. Afterward, the solution was removed and dried under vacuum to obtain 8 (59 mg, quantitative). The compound was pure enough for direct use without further purification.

[0182] Compound 12.

[0183]

[0184] A solution of lipoic acid (3 mmol) and CDI (3.9 mmol) was dissolved in 25 ml of anhydrous DCM. This solution was added dropwise to 5 ml of anhydrous DCM containing 8 mmol of N-methyl-1,3-propanediamine at 0°C. The reaction mixture was stirred at 0°C for 40 minutes and at room temperature for 30 minutes, then washed three times with H2O, dried over MgSO4, filtered, and concentrated to obtain 12 (589 mg, 66%). 1 H NMR (600 MHz, CDCl3): δ 3.57-3.50 (m, 1H), 3.31 (q, J = 5.8 Hz, 2H), 3.17-3.12 (m, 1H), 3.11-3.05 (m, 1H), 2.65 (t, J = 6.0 Hz, 2H), 2.46-2.40 (m, 1H), 2.39 (s, 3H), 2.15-2.11 (m, 2H), 1.91-1.84 (m, 1H), 1.72-1.54 (m, 6H), 1.49-1.37 (m, 2H). HRMS (ESI) Calculated C 12 H 26 N2OS2[M+H] + m / z 277.1408; measured: 277.1399.

[0185] Compound 13.

[0186]

[0187] Compound 13 was synthesized and characterized according to a published protocol. 1¹H NMR (600 MHz, CDCl3): δ 4.50-4.38 (m, 4H), 4.19-4.15 (m, 2H), 1.74-1.70 (m, 2H), 1.38-1.20 (m, 12H), 0.89 (t, J = 7.2 Hz, 3H). Synthesis was performed according to the literature [Liu, S. et al., Zwitterionic Phospholipidation of Cationic Polymers Facilitates Systemic mRNA Delivery to Spleen and Lymph Nodes. J. Am. Chem. Soc. 2021, 143, 21321-21330] (the full text of which is incorporated herein by reference).

[0188] Compound 14.

[0189]

[0190] A solution of 12 (0.25 mmol) in 1 ml of anhydrous DMF was added to 13 (0.25 mmol), and the reaction mixture was stirred at 70°C for 24 hours. The mixture was concentrated and dried under vacuum to obtain 14 (116 mg, 90%). 1 H NMR (600 MHz, MeOD): δ 7.90 (s, 1H), 4.14-4.01 (m, 1H), 3.91-3.83 (m, 1H), 3.73-3.67 (m, 1H), 3.62-3.55 (m, 1H), 3.28 (t, J = 6.6 Hz, 2H), 3.21-3.15 (m, 1H), 3.13-3.06 (m, 1H), 2.98 (t, J = 7.2 Hz, 2H), 2.69 (s, 3H), 2.50-2.41 (m, 1H), 2.24 (t, J = 7.2 Hz, 2H), 1.93-1.84 (m, 1H), 1.76-1.59 (m, 6H), 1.51-1.43 (m, 2H), 1.43-1.37 (m,1H), 1.36-1.25 (m, 5H), 0.92-0.88 (m, 3H). 1313C NMR (150 MHz, MeOD): δ 177.08, 79.68, 57.79, 48.91, 48.77, 48.04, 41.54, 39.55, 37.06, 36.91, 35.91, 33.85, 33.20, 32.09, 32.05, 30.44, 30.12, 27.73, 27.16, 26.81, 23.92, 14.65. HRMS (ESI) calculated value C 22 H 44 N2O5PS2[MH] - m / z 511.2429; measured: 511.2423.

[0191] Manufacturing of an exemplary discloser of the present disclosure

[0192] Nine exemplary initiators, initiators I2, I3, I4, I5, I6, I7, I8, I9, and I10, are described herein. Initiators I2 (Compound 34), I3 (Compound 39), and I4 (Compound 37) were prepared according to Reaction Schemes 4, 5, and 6. Initiators I5 (Compound 16), I6 (Compound 43), I7 (Compound 44), I8 (Compound 40), I9 (Compound 49), and I10 (Compound 54) were prepared according to Reaction Schemes 7, 8, 9, and 10. The compounds obtained at each step of the schemes were identified by NMR. Further details and data are described below.

[0193] Additionally, a control initiator I1 was prepared in this example. I1, which does not possess a glycan head, is an initiator without a specific targeting preference and was prepared to form a copolymer of the exemplary propagator of this disclosure to characterize the propagator. Initiator I1 has the following structure:

[0194]

[0195] Reaction Equation 4

[0196]

[0197] Reaction Equation 5

[0198]

[0199] Reaction Equation 5 (continued)

[0200]

[0201] Reaction Equation 6

[0202]

[0203] Reaction Equation 7

[0204]

[0205] Reaction Equation 8

[0206]

[0207] Reaction Equation 9

[0208]

[0209] Reaction Equation 10

[0210]

[0211] Compound 15 8 .

[0212]

[0213] Compound 15 was synthesized and characterized according to a published protocol. 1H NMR (600 MHz, MeOD): δ 6.93 (d, J = 8.6 Hz, 2H), 6.71 (d, J = 8.6 Hz, 2H), 5.3 (s, 1H), 4.00–3.99 (m, 1H), 3.89–3.88 (m, 1H), 3.81–3.79 (m, 1H), 3.79–3.70 (m, 2H), 3.69–3.67 (m, 1H).

[0214] Compound 16.

[0215]

[0216] EDC (0.24 mmol), HOBt (0.24 mmol), trimethylamine (0.4 mmol), and 3-mercaptopropionic acid (0.2 mmol) were added to a solution of 15 (0.24 mmol) in 2 mL of DMF, and the resulting solution was stirred under nitrogen at room temperature for 2 hours. The mixture was concentrated and dried under vacuum, and the crude product was purified by column chromatography (MeOH / DCM 1:2) on silica gel to obtain 16 (72%). 1 H NMR (600 MHz, MeOD) δ 6.94 (d, J = 8.6 Hz, 2H), 6.72 (d, J = 8.6 Hz, 2H), 5.30 (s, 1H), 4.00 (dd, J = 3.4, 1.8 Hz, 1H), 3.89 (dd, J = 9.7, 3.4 Hz, 1H), 3.81-3.67 (m, 4H), 2.72 (t, J = 6.8 Hz, 2H), 2.60 (t, J = 6.8 Hz, 2H). 13 C NMR (150 MHz, MeOD) δ 176.55, 151.13, 143.23, 119.25(x2), 117.93 (x2), 101.49, 101.32, 75.10, 72.43, 72.18, 68.42, 62.66, 40.34, 20.70. HRMS (ESI) Calculated C 15 H 22 NO7S [M+H] + : 360.1117, measured value 360.1101.

[0217] Compounds 17-20. Compounds 17-20 were synthesized according to the literature [Peng, W.; Paulson, JC, CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells. J. Am. Chem. Soc. 2017, 139, 12450-12458] (the full text of which is incorporated herein by reference).

[0218] Compounds 21-25. Compounds 21-25 were synthesized according to the literature [Chien, W.-T., et al., Sequential one-pot enzymatic synthesis of oligo-N-acetyllactosamine and its multi-sialylated extensions. Chem. Commun. 2014, 50, 5786-5789].

[0219] Compound 26. EDC (0.52 mmol), HOBt (0.52 mmol), trimethylamine (0.86 mmol), and 3-mercaptopropionic acid (0.47 mmol) were added to Compound 25 (0.43 mmol) in DCM (5 mL), and the resulting solution was stirred under nitrogen at room temperature for 2 hours. The mixture was concentrated and dried under vacuum, and the crude product was purified by column chromatography (MeOH / DCM 1:10) on silica gel to obtain 26 (184 mg, 80%). 1 H NMR (600 MHz, CDCl3) δ 5.96 (d, J = 8.6 Hz, 1H), 5.28 (t, J = 9.6 Hz, 1H), 5.05 (t, J = 9.4 Hz, 1H), 4.64 (d, J = 8.4 Hz, 1H), 4.24 (dd, J = 12.3, 4.7 Hz, 1H), 4.11 (dd, J = 12.3, 2.5 Hz, 1H), 3.86-3.80 (m, 2H), 3.68-3.66 (m, 1H), 3.47-3.43 (m, 1H), 3.34-3.29 (m, 1H), 3.22-3.16 (m, 1H), 2.81 (t, J = 8.2 Hz, 2H), 2.51-2.45 (m, 2H), 2.06 (s, 3 H), 2.01 (s, 3 H), 2.00 (s, 3 H), 1.93 (s, 3 H), 1.57-1.51 (m, 4H), 1.48 (t, J = 7.0 Hz, 2H) 1.37-1.29 (m, 4H). HRMS (ESI) Calculated Value C 23 H 38 N2O 10 S [M+H] + : 535.2325, measured value 535.2314. Synthesis was performed according to the literature [Maklakova, SY et al., Cellular uptake of N-acetyl-d-galactosamine-, N-acetyl-d-glucosamine- and d-mannose-containing fluorescent glycoconjugates investigated by liver intravital microscopy. Carbohydr. Res. 2020, 489, 107928] (the full text of which is incorporated herein by reference).

[0220] Compound 27. NaOMe was added to Compound 26 in MeOH, and the resulting solution was stirred at room temperature under nitrogen for 2 hours. The mixture was neutralized by IR-120, filtered, and concentrated and dried under vacuum to obtain 27 (92 mg, quantitative). 1 H NMR (600 MHz, MeOD) δ 4.38 (d, J = 9.2 Hz, 1H), 3.90-3.86 (m, 2H), 3.68 (dd, J = 12.9, 5.9 Hz, 1H), 3.65-3.62 (m, 1H), 3.48-3.43 (m, 2H), 3.28-3.24 (m, 1H), 3.20-3.14 (m, 2H), 2.94 (t, J = 7.3 Hz, 1H), 2.73 (t, J = 7.3 Hz, 1H), 2.59 (t, J = 7.3 Hz, 1H), 2.47 (t, J = 7.3 Hz, 1H), 1.97 (s, 3 H), 1.56-1.48 (m, 4H), 1.39-1.35 (m, 4H). 1313C NMR (150 MHz, MeOD): δ 173.70, 169.75, 102.74, 77.92, 76.07, 70.50, 62.76, 57.35, 41.02, 40.32, 36.45, 35.19, 30.49, 27.66, 26.73, 23.03. HRMS (ESI) calculated value C 17 H 32 N2O 17 S [M+H] + : 409.2008, measured value 409.2017.

[0221] 9 Am Neu5Ac-α2,3-SCT 30, 9 Am Preparation of Neu5Ac-α2,6-SCT 31 and Neu5Ac-α2,3-SCT 38. According to the literature [Lin, C.-W., et al., Homogeneous antibody and CAR-T cells with improved effector functions targeting SSEA-4 glycan on pancreatic cancer. Proceedings of the National Academy of Sciences 2021, 118, e2114774118] (the full text incorporated herein by reference), 30 mg sialyl glycopeptide (SGP) was digested with Endo-S WT (300 μg) in Tris-HCl buffer at 37°C for 48 hours, purified by Sephadex G-25 gel filtration chromatography, and the product was analyzed by ESI-MS to obtain SCT compound 28. Neuraminidase (5 U / ml, 12 μL) in Tris-HCl buffer was added to the mixture at 37°C for 12 hours, and desiallylated N-glycan 29 was obtained by purification via Sephadex G-25 gel filtration chromatography. Subsequently, the reaction was carried out at 100 mM 9 AmThe experiment was carried out in 0.5 mL of HEPES buffer (50 mM, pH 8.5) containing Neu5Ac (14.5 mg, 47 μmol), 110 mM CTP (27.2 mg, 52 μmol), and 20 mM MgCl2. The pH of the reaction mixture was adjusted to 8.5 by adding 2 N NaOH. Subsequently, 0.5 mg / mL of NmCSS was added to the solution. The resulting mixture was incubated at 37°C for 8 hours, and CMP-9 Am The formation of Neu5Ac was monitored by TLC analysis.

[0222] 9 Am In the case of Neu5Ac-α2,6-SCT, in accordance with the literature [Peng, W., et al., Recent H3N2 Viruses Have Evolved Specificity for Extended, Branched Human-type Receptors, Conferring Potential for Increased Avidity. Cell Host Microbe 2017, 21, 23-34] (the full text of which is incorporated herein by reference), hST6Gal-I (0.5 mg / mL) with N-glycans 9 Am It was added to the Neu5Ac reaction mixture and incubated at 37°C. 9 Am In the case of Neu5Ac-α2,3-SCT, PmST3 (0.3 mg / mL) with N-glycans 9 Am It was added to the Neu5Ac reaction mixture and incubated at 37°C. For Neu5Ac-α2,3-SCT, PmST3 (0.3 mg / mL) was added to the Neu5Ac reaction mixture with N-glycan and incubated at 37°C. The reaction was monitored by mass spectrometry analysis and TLC. After the receiver was consumed, the reaction mixture was centrifuged, and the supernatant was passed through a centrifuge filter (Amicon Ultra, Millipore) with a molecular mass cutoff of 10 kDa to remove proteins. The filtrate was purified by P-2 gel filtration chromatography 9Am Neu5Ac-α2,3-SCT 30, 9 Am Neu5Ac-α2,6-SCT 31 and Neu5Ac-α2,3-SCT 38 were obtained.

[0223] 9 BPC Neu5Ac-α2,6-SCT-SH 34, 9 TCC Preparation of Neu5Ac-α2,3-SCT-SH 37 and Neu5Ac-α2,3-SCT-SH 39. 9 Am Neu5Ac-α2,6-SCT and DIEA (5.0 equivalents) were dissolved in H2O, followed by the addition of biphenylcarboxylic acid-N-hydroxysuccinimide ester (BPC-NHS) (3 equivalents) in THF. The reaction mixture was stirred at 0°C until the starting materials were consumed. Subsequently, the reaction mixture was purified using a Sep-Pac C18 column (2 g, Waters Corporation) and eluted with H2O-MeOH to obtain Compound 32 in 91% yield. 9 Am Compound 35 was obtained by preparing Neu5Ac-α2,3-SCT in a manner similar to that described above by stirring with 4H-thieno[3,2-c]cromen-2-carbamoyl-NHS (TCC-NHS) in THF and H2O. After purification, the product was obtained in a 91% yield.

[0224] Water 9 BPC Neu5Ac-α2,6-SCT 32 or 9 TCC A mixture of Neu5Ac-α2,3-SCT 35 was added to CDMBI and TEA and incubated at 4°C for 1 hour to produce the corresponding oxazoline N-glycans 33 and 36, respectively. Subsequently, these were purified by Sephadex G-25 gel filtration chromatography and characterized by ESI-MS. GlcNAc-SH 27 (0.25 mg) and Endo-M(N175Q) (1.6 U / mL) were 9 BPCIt was added to a solution of 50 mM phosphate buffer (pH 7) containing Neu5Ac-α2,6-SCT-oxazoline and incubated at 30°C for 30 minutes. The transglycosylation product was isolated by P-2 gel filtration chromatography to obtain compound 34, which was characterized by ESI-MS. 9 TCC Neu5Ac-α2,3-SCT-SH 37 and Neu5Ac-α2,3-SCT-SH 39 were prepared in the same manner as described above.

[0225] Compound 34.9 BPC Neu5Ac-α2,6-SCT-SH. 1 H NMR (600 MHz, DMSO-d6): δ = 8.33 (s, 3H, NH), 8.00 (d, J = 8.6 Hz, 4H), 7.72 (dd, J = 8.0, 14.2 Hz, 9H), 7.49 (t, J = 8.3 Hz, 4H), 7.40 (t, J = 8.3 Hz, 2H), 4.98-4.95 (m, 2H), 4.76 (s, 1H), 4.54 (s, 1H), 4.44-4.39 (m, 2H), 4.25-4.22 (m, 3H), 3.99 (s, 1H), 3.87 (s, 1H), 3.83-3.73 (m, 5H), 3.41-3.25 (m, 58H), 3.21 - 3.16 (m, 3H), 3.11 - 2.99 (m, 4H), 2.87 (t, J = 6.9 Hz, 2H), 2.61 (d, J = 8.4 Hz, 2H), 2.44 (t, J = 7.4 Hz, 2H), 1.91-1.77 (m, 18H), 1.44 (t, J = 6.9 Hz, 2H), 1.39-1.28 (m, 4H), 1.28-1.19 (m, 4H), 1.12 (t, J = 6.9 Hz, 1H). HRMS (ESI) Calculated C 119 H 171 N9O 63 S 2- [M-2H] 2- : 1383.0093, measured value 1383.0077.

[0226] 화합물 37.9 TCC Neu5Ac-α2,3-SCT-SH. 1 H NMR (600 MHz, DMSO-d6): δ = 8.22 (s, 3H, NH), 8.10-8.09 (m, 1H, NH), 7.96-7.93 (m, 1H, NH), 7.81-7.79 (m, 1H, NH), 7.74-7.72 (m, 1H, NH), 7.35 (d, J = 7.8 Hz, 2H), 7.29 (s, 2H), 7.20 (t, J = 7.8 Hz, 2H), 6.97 (t, J = 7.8 Hz, 2H), 6.92 (d, J = 7.9 Hz, 2H), 5.29 (s, 4H), 5.01-4.95 (m, 2H), 4.77 (s, 1H), 4.54 (s, 1H), 4.44-4.36 (m, 2H), 4.27-4.19 (m, 3H), 3.99 (s, 1H), 3.88 (s, 1H), 3.85-3.71 (m, 3H), 3.50-3.22 (m, 52H), 3.19 (d, J = 9.5 Hz, 2H), 3.10-3.00 (m, 4H), 2.87 (t, J = 6.9 Hz, 2H), 2.64 - 2.58 (m, 2H), 2.44 (t, J = 7.4 Hz, 2H), 1.93-1.78 (m, 18H), 1.45-1.39(m, 2H), 1.39-1.29 (m, 4H), 1.28-1.20 (m, 4H), 1.16 (t, J = 6.9 Hz, 1H). HRMS (ESI) 계산치 C 117 H 169 N9O 65 S3 2- [M-2H] 2- : 1416.9606, 실측치 1416.9623.

[0227] 화합물 39. Neu5Ac-α2,3-SCT-SH 1H NMR (600 MHz, DMSO-d6): δ = 8.33 (s, 3H, NH), 8.10 (s, 1H, NH), 7.96-7.94 (m, 1H, NH), 7.81-7.80 (m, 1H, NH), 7.74-7.73 (m, 1H, NH), 4.98-4.95 (m, 2H), 4.76-4.75 (m, 1H), 4.54 (s, 1H), 4.46-4.38 (m, 2H), 4.25-4.22 (m, 3H), 3.99 (s, 1H), 3.87 (s, 1H), 3.80-3.71 (m, 4H), 3.41-3.25 (m, 59H), 3.23 - 3.18 (m, 3H), 3.08 - 3.01 (m, 3H), 2.87 (t, J = 6.9 Hz, 2H), 2.63-2.60 (m, 2H), 2.44 (t, J = 7.4 Hz, 2H), 1.87-1.79 (m, 18H), 1.44 (t, J = 6.9 Hz, 2H), 1.39-1.28 (m, 4H), 1.28-1.19 (m, 4H), 1.07 (t, J = 6.9 Hz, 1H). HRMS (ESI) Calculated C 93 H 153 N7O 63 S 2- [M-2H] 2- : 1203.9357, measured value 1203.9377.

[0228] Compound 40.

[0229]

[0230] EDC (0.12 mmol), HOBt (0.12 mmol), DMAP (0.12 mmol), trimethylamine (0.2 mmol) and CT (PEG) in compound 15 (0.12 mmol) in DMF (1 mL) 12(0.1 mmol) was added, and the resulting solution was stirred at room temperature under nitrogen for 12 hours. The mixture was concentrated and dried under vacuum, and the crude product was purified by column chromatography on silica gel to obtain 40 (59%). 1H NMR (600 MHz, MeOD): δ 6.93 (d, J = 8.6 Hz, 2H), 6.71 (d, J = 8.6 Hz, 2H), 5.3 (s, 1H), 4.00-3.99 (m, 1H), 3.89-3.88 (m, 1H), 3.81-3.70 (m, 5H), 3.70-3.59 (m, 48H), 2.68 (t, J = 6.8 Hz, 2H), 2.50-2.47 (m, 2H). 13 C NMR (150 MHz, MeOD): δ 170.17, 151.03, 143.50, 119.26(x2), 117.82(x2), 101.36, 75.10, 74.08, 72.45, 72.19, 71.45, 71.41, 71.37, 71.30, 71.24, 71.11, 70.93(x18), 68.43, 62.68, 24.67. HRMS (ESI) Calculated C 39 H 70 NO 19 S [M+H] + : 888.4263, measured value 888.4241.

[0231] Compounds 41-42. Compounds 41 and 42 were synthesized according to the literature [Lee, H.-K. et al., Reactivity-Based One-Pot Synthesis of Oligomannoses: Defining Antigens Recognized by 2G12, a Broadly Neutralizing Anti-HIV-1 Antibody. Angew. Chem. Int. Ed. 2004, 43, 1000-1003] (the full text of which is incorporated herein by reference).

[0232] Compound 43.

[0233]

[0234] EDC (0.24 mmol), HOBt (0.24 mmol), trimethylamine (0.4 mmol), and 3-mercaptopropionic acid (0.2 mmol) were added to a solution of 42 (0.24 mmol) in 2 mL of DMF, and the resulting solution was stirred under nitrogen at room temperature for 2 hours. The mixture was concentrated and dried under vacuum, and the crude product was purified by column chromatography (MeOH / DCM 1:3) on silica gel to obtain 16 (81%). 1 H NMR (600 MHz, MeOD) δ 4.91 (s, 1H), 3.84 (dd, J = 3.4, 1.8 Hz, 1H), 3.82-3.76 (m, 2H), 3.75-3.67 (m, 2H), 3.62 (m, 1H), 3.56-3.41 (m, 2H), 2.94 (t, J = 7.0 Hz, 2H), 2.70 (t, J = 7.2 Hz, 2H), 2.48 (t, J = 7.2 Hz, 2H). HRMS (ESI) calculated value C 14 H 28 NO7S [M+H] + : 354.1586, measured value 354.1602.

[0235] Compound 44.

[0236]

[0237] EDC (0.12 mmol), HOBt (0.12 mmol), trimethylamine (0.2 mmol) and CT (PEG) in compound 42 (0.12 mmol) in DMF (1 mL) 12 (0.1 mmol) was added, and the resulting solution was stirred at room temperature under nitrogen for 12 hours. The mixture was concentrated and dried under vacuum, and the crude product was purified by column chromatography on silica gel to obtain 44 (62%). 1H NMR (600 MHz, D2O): δ 4.77 (d, J = 8.6 Hz, 2H), 3.85-3.82 (m, 1H), 3.81-3.77 (m, 1H), 3.69-3.67 (m, 1H), 3.66-3.64 (m, 2H), 3.63-3.57 (m, 41H), 3.55-3.45 (m, 4H), 2.88 (t, J = 6.8 Hz, 2H), 2.57 (t, J = 7.2 Hz, 2H), 2.37 (t, J = 7.2 Hz, 2H), 1.66-1.51 (m, 4H), 1.40-1.31 (m, 2H). 13 C NMR (150 MHz, D2O): δ 171.01, 99.62, 72.72, 70.57, 69.99, 69.24 (x22), 69.04, 67.90, 67.39, 66.73, 60.92, 39.36, 37.57, 27.96, 26.70, 22.91, 22.43. HRMS (ESI) 38 H 76 NO 19 S [M+H] + : 882.4732, location 882.4750.

[0238] compound 45

[0239]

[0240] Compound 15b (5 mmol) in MeOH was added to NaOMe (0.2 equivalents), and the resulting solution was stirred at room temperature under nitrogen for 2 hours. The mixture was neutralized by IR-120, filtered, and concentrated and dried under vacuum. Subsequently, this was dissolved in anhydrous DCM (40 mL), treated with imidazole (7.5 mmol) at 0°C, and then TBDPSCl (5.5 mmol) was added. The mixture was stirred at room temperature under a nitrogen atmosphere for 2.5 hours. The reaction mixture was quenched by the addition of MeOH. After stirring at room temperature for 10 minutes, the solvent was removed under reduced pressure to obtain the dry residue, which was purified by column chromatography using MeOH / DCM (1 / 10) to obtain Compound 45 (75%). 1 H NMR (600 MHz, CDCl3) δ 7.61 (m, 4H), 7.41-7.29 (m, 11H), 7.23-7.18 (m, 2H), 6.92 (d, J = 9.3 Hz, 2H), 5.41 (s, 1H), 5.16 (s, 2H), 4.09 (s, 1H), 4.02-4.00 (dd, J = 9.3, 3.4 Hz, 1H), 3.91 (t, J = 9.3 Hz, 1H), 3.85 (d, J = 5.1 Hz, 2H), 3.72-3.69 (m, 1H), 1.01, (s, 9H). 13 C NMR (150 MHz, CDCl3): 162.61, 135.64(x4), 135.54(x4), 132.73, 129.95(x4), 128.64(x4), 128.38, 128.33, 127.84(x2), 127.81(x2), 98.09, 71.41, 71.22, 70.22, 70.13, 64.89, 36.53, 31.48, 26.83(x3), 19.19. HRMS (ESI) Calculated C 36 H 42 NO8Si [M+H] + : 644.2680, measured value 644.2699.

[0241] Compound 46.

[0242]

[0243] Trimethyl orthobenzoate (9 mmol) was added to a solution of compound 45 (3 mmol) and a catalytic amount of CSA (0.3 mmol) in CH3CN (60 mL) at room temperature under atmospheric pressure of nitrogen. After stirring for 30 minutes, Et3N was added to quench the reaction mixture, and the resulting mixture was dried under reduced pressure. The residue was purified by column chromatography using EA / Hex (1 / 2) to obtain compound 46 (81%). 1 H NMR (600 MHz, CDCl3) δ 7.65-7.59 (m, 2H), 7.57-7.52 (m, 4H), 7.41-7.27 (m, 14H), 7.26-7.20 (m, 2H), 6.93 (d, J = 9.2 Hz, 2H), 5.77 (s, 1H), 5.17 (s, 2H), 4.70 (d, J = 6.1 Hz,1H), 4.58 (dd, J = 9.3, 3.4 Hz, 1H), 3.79-3.76 (m, 2H), 3.74-3.70 (m, 1H), 3.69-3.66 (m, 1H), 3.22 (s, 3H), 2.53 (d, J = 3.9 Hz, 1H), 0.93, (s, 9H). 13 C NMR (150 MHz, CDCl3): 171.23, 153.49, 152.24, 137.09, 136.09, 135.68(x4), 135.48(x4), 132.98, 132.72, 129.86, 129.84(x2), 129.18, 128.65(x2), 128.39, 128.37, 128.34, 127.78(x2), 127.71(x2), 126.23, 121.11, 117.18, 95.69, 79.52, 69.57, 69.45, 67.03, 63.75, 60.44, 51.16, 26.76(x3), 19.15, 14.22. HRMS (ESI) Calculated Value C 44 H 48 NO9Si [M+H]+ :762.3098, measured value 762.3072.

[0244] Compound 47.

[0245]

[0246] Compound 46 (2 mmol) was dissolved in DCM (20 mL) and sequentially mixed with DIPEA (6 mmol), benzoic anhydride (4 mmol), and DMAP (0.2 mmol). After stirring for 30 minutes, the solvent was evaporated under reduced pressure to obtain a dry residue, which was then poured into EA (20 mL) and 2 N HCl (20 mL) while stirring vigorously for 30 minutes. The solvent was removed by evaporation and then extracted with EA. The collected organic layer was washed with ice-cold saturated NaHCO3 (aqueous), water, and brine, and dried over MgSO4. The filtrate was evaporated under reduced pressure and redissolved in THF (20 mL). AcOH (4 mmol) and 1 M TBAF (2.4 mmol in THF) were added at 0°C. The resulting mixture was slowly heated to room temperature and stirred for an additional 2 hours, then diluted with EA. The organic layer was washed with saturated NaHCO3 (aqueous), water, and brine, dried with anhydrous MgSO4, and concentrated under reduced pressure. The dried residue was purified by column chromatography using EA / Hex (1 / 2) to obtain compound 47 (65%). 1 H NMR (600 MHz, CDCl3) δ 8.10-8.05 (m, 4H), 7.61-7.56 (m, 2H), 7.48-7.41 (m, 4H), 7.39-7.27 (m, 7H), 7.03 (d, J = 9.2 Hz, 2H), 5.69 (s, 1H), 5.62-5.55 (m, 2H), 5.16, (s, 2H), 4.62 (dd, J = 9.3, 3.4 Hz, 1H), 4.06-4.01 (m, 1H), 3.76-3.67 (m, 2H). 13C NMR (150 MHz, CDCl3): 167.42, 166.05, 153.55, 152.01, 136.03, 133.84, 133.76, 130.00 (x4), 129.09, 128.96, 128.69(x4), 128.65(x4), 128.62(x4), 128.34, 117.11 (x2), 96.18, 72.61, 71.30, 70.01, 68.53, 61.16. HRMS (ESI) Calculated C 34 H 32 NO 10 [M+H] + :614.2026, measured value 614.2038.

[0247] Compound 48.

[0248]

[0249] A stirred solution of 47 (0.2 mmol) and 4 A molecular sieve (0.2 g) in anhydrous DCM (2 mL) was cooled to -40°C, and then BF3(OEt)2 (0.02 mmol) was added dropwise to the solution. A solution of 15a in anhydrous DCM was added dropwise to the mixture and stirred at -40°C for 1 hour. Afterward, the reaction mixture was slowly heated to room temperature and stirred for an additional 1 hour. The solution was quenched with the addition of triethylamine, filtered, saturated aqueous NaHCO3 was added, and extracted with DCM. The organic layer was dried with MgSO4 and evaporatively dried. The residue was purified by flash column chromatography on silica gel to obtain the trisaccharide product. Subsequently, the product was dissolved in MeOH, NaOMe (0.2 equivalents) was added, and the resulting solution was stirred at room temperature for 2 hours. The mixture was neutralized with IR-120, filtered, and concentrated and dried under vacuum. The deacetylated mixture was purified by Bio-Gel P-2 (Bio-Rad) using H2O as the eluent to obtain pure trisaccharides. The compound was freeze-dried, dissolved in MeOH (2 mL), 10% Pd-C (30 mg) was added, and vigorously stirred overnight under an H2 atmosphere. The solution was filtered through Celite and concentrated and dried to obtain compound 48 (42%). 1 H NMR (600 MHz, DO) δ 7.03 (d, J = 9.2 Hz, 2H), 6.88 (d, J = 9.2 Hz, 2H), 5.48 (s, 1H), 5.19 (s, 1H), 4.76 (s, 1H), 4.32 (s, 1H), 4.14 (dd, J = 9.3, 3.0 Hz, 1H), 4.11 (s, 1H), 3.95-3.63 (m, 15H). 1313C NMR (150 MHz, D2O): 151.38, 143.39, 121.23, 120.70, 105.19, 101.60, 101.39, 80.93, 76.13, 75.38, 74.04, 73.27, 73.12, 72.79, 72.66, 72.22, 69.50, 69.41, 68.70, 67.90, 63.71, 63.65. HRMS (ESI) calculated value C 24 H 37 NO 16 Na[M+Na] + :618.2010, measured value 618.2029.

[0250] Compound 49.

[0251]

[0252] EDC (0.12 mmol), HOBt (0.12 mmol), DMAP (0.12 mmol), trimethylamine (0.2 mmol) and CT (PEG) in compound 48 (0.12 mmol) in DMF (1 mL) 12 (0.1 mmol) was added, and the resulting solution was stirred at room temperature under nitrogen for 12 hours. The mixture was concentrated and dried under vacuum, and the crude product was purified using H2O as the eluent for Bio-Gel P-2 gel to obtain 49 (54%). 1 H NMR (600 MHz, DO): 7.20 (d, J = 9.2 Hz, 2H), 7.13 (d, J = 9.2 Hz, 2H), 5.53 (s, 1H), 5.09 (s, 1H), 4.65 (s, 1H), 4.25 (s, 1H), 4.06 (dd, J = 9.3, 3.0 Hz, 1H), 4.01 (m, 1H), 3.83-3.67 (m, 11H), 3.61-3.56 (m, 52H), 2.64 (t, J = 6.4 Hz, 2H), 2.48 (t, J = 6.4 Hz, 2H). 1313C NMR (150 MHz, D2O): 178.06, 153.84, 149.84, 123.02, 118.11, 120.42, 98.8, 97.78, 78.05, 73.39, 72.61, 72.17, 71.47, 70.52, 70.35, 70.01, 69.85, 69.55, 69.38, 69.31, 69.17, 66.97, 66.74, 66.60, 65.82, 65.10, 60.96, 60.86, 35.82, 23.03. HRMS (ESI) Calculated Value C 51 H 89 NO 29 SNa[M+Na] + :1234.5139, measured value 1234.5114.

[0253] Compound 51.

[0254]

[0255] Trichloroacetonitrile and DBU were added to a stirred solution of 50 (1 mmol) in anhydrous DCM (10 mL), and the solution was stirred at room temperature for 2 hours. The solvent was removed, and the residue was purified by flash column chromatography on silica gel to obtain the imidate product. A stirred solution of benzyl(4-hydroxyphenyl)carbamate (1.2 mmol) and 4 A molecular sieve (1 g) in anhydrous DCM (10 mL) was cooled to -40°C, and then BF3(OEt)2 (0.1 mmol) was added dropwise to the solution. A solution of the imidate donor (1 mmol) in anhydrous DCM was added dropwise to the mixture and stirred at -40°C for 1 hour. Afterward, the reaction mixture was slowly heated to room temperature and stirred for an additional 1 hour. The solution was quenched with the addition of triethylamine, filtered, saturated aqueous NaHCO3 was added, and extracted with DCM. The organic layer was dried with MgSO4 and evaporated. The residue was purified by flash column chromatography on silica gel to obtain compound 51 (72%). 1H NMR (600 MHz, CDCl3) δ 7.40-7.28 (m, 18H), 7.19 (d, J = 7.9 Hz, 2H), 7.10 (d, J = 8.1 Hz, 2H), 7.00 (d, J = 8.1 Hz, 2H), 5.57-5.55 (m, 2H), 5.12 (s, 2H), 4.91 (d, J = 10.5 Hz, 1H), 4.80 (d, J = 10.5 Hz, 1H), 4.69 (d, J = 10.5 Hz, 1H), 4.65 (d, J = 10.5 Hz, 1H), 4.53 (d, J = 10.5 Hz, 1H), 4.46 (d, J = 10.5 Hz, 1H), 4.22 (dd, J = 9.4, 3.6 Hz, 1H), 4.07-4.04 (t, J = 9.7 Hz, 1H), 3.93 (d, J = 9.5 Hz, 1H), 3.83 (dd, J = 10.9, 3.9 Hz, 1H), 3.68 (d, J = 10.8 Hz, 1H), 2.21 (s, 3H). 13 C NMR (150 MHz, CDCl3):170.44, 156.25, 154.62, 138.27, 138.04, 137.82, 136.51, 132.71, 129.79, 128.50, 128.43, 128.31, 128.27, 128.10, 128.08, 127.83, 127.80, 127.64, 127.60, 116.63, 96.13, 77.95, 76.66, 75.22, 74.00, 73.34, 71.99, 71.92, 68.55, 68.5, 66.63, 21.09. HRMS (ESI) 계산치 C 43 H 43 NO 10 [M+H] + :718.3016, 실측치 718.3041.

[0256] 화합물 52.

[0257]

[0258] NaOMe (0.1 equivalent) was added to a stirred solution of 51 (0.6 mmol) in MeOH, and the resulting solution was stirred at room temperature for 1 hour. The mixture was neutralized with IR-120, filtered, and concentrated and dried under vacuum. Subsequently, the deacetylation product was dissolved in anhydrous DCM (5 mL), and 4 A molecular sieve (0.5 g) was added. The solution was cooled to -40°C, and BF3(OEt)2 (0.05 mmol) was added dropwise to it. A solution of an imidate donor (0.5 mmol) in anhydrous DCM was added dropwise to the mixture, and the mixture was stirred at -40°C for 1 hour. Afterward, the reaction mixture was slowly heated to room temperature and stirred for an additional 1 hour. The solution was quenched with triethylamine, filtered, saturated aqueous NaHCO3 was added, and extracted with DCM. The organic layer was dried with MgSO4 and evaporatively dried. Next, the product was dissolved in MeOH, NaOMe (0.1 equivalent) was added, and the resulting solution was stirred at room temperature for 2 hours. The mixture was neutralized by IR-120, filtered, and concentrated and dried under vacuum. The residue was purified by flash column chromatography on silica gel to obtain compound 52 (69%). 1H NMR (600 MHz, CDCl3) δ 7.36-7.25 (m, 25H), 7.22-7.13 (m, 10H), 6.99-6.93 (m, 4H), 5.66 (s, 1H), 5.17 (s, 1H), 5.06 (s, 2H), 4.86 (d, J = 10.5 Hz, 1H), 4.79 (d, J = 10.5 Hz, 1H), 4.73, (s, 2H), 4.65 (d, J = 10.5 Hz, 1H), 4.58-4.57 (m, 2H), 4.55-4.52 (m, 2H), 4.47-4.43 (m, 3H), 4.19-4.14 (m, 2H), 3.99-3.96 (m, 2H), 3.88 (dd, J = 9.1, 3.1 Hz, 1H), 3.84-3.76 (m, 3H), 3.67-3.63 (m, 3H). 13 C NMR (150 MHz, CDCl3): 156.22, 154.70, 138.47, 138.35, 138.18, 138.14, 138.05, 137.90, 136.51, 132.30, 129.74, 129.63, 128.46, 128.44, 128.31, 128.28, 128.26, 128.19, 128.06, 127.93, 127.85, 127.83, 127.74, 127.68, 127.60, 127.54, 127.46, 127.38, 127.32, 116.63, 101.12, 96.95, 79.97, 79.42, 77.21, 77.00, 76.78, 75.12, 75.02, 74.66, 74.45, 74.33, 73.23, 73.16, 72.44, 72.41, 72.16, 71.69, 68.99, 68.45, 66.57. HRMS (ESI) 계산치 C 68 H 70 NO 13 [M+H] + :1108.4847, 실측치 1108.4819

[0259] 화합물 53.

[0260]

[0261] 4. A stirred solution of 52 (0.3 mmol) in anhydrous DCM (2.5 mL) was added along with a molecular sieve (0.25 g). The solution was cooled to -40°C, and then BF3(OEt)2 (0.03 mmol) was added dropwise. A solution of an imidate donor (0.3 mmol) in anhydrous DCM was added dropwise to the mixture, and the mixture was stirred at -40°C for 1 hour. Afterward, the reaction mixture was slowly heated to room temperature and stirred for an additional 1 hour. The solution was quenched with triethylamine, filtered, saturated aqueous NaHCO3 was added, and extracted with DCM. The organic layer was dried with MgSO4 and evaporatively dried. The residue was purified by flash column chromatography on silica gel to obtain the trisaccharide product. Next, the product was dissolved in MeOH, NaOMe (0.1 equivalent) was added, and the resulting solution was stirred at room temperature for 2 hours. The mixture was neutralized with IR-120, filtered, and concentrated and dried under vacuum. Next, the compound was dissolved in MeOH (2 mL), 10% Pd-C (30 mg) was added, and the mixture was stirred vigorously overnight under an H2 atmosphere. The solution was filtered through Celite and concentrated and dried to obtain compound 53 (60%). 1 H NMR (600 MHz, DO) δ 7.03 (d, J = 9.0 Hz, 2H), 6.83 (d, J = 9.0 Hz, 2H), 5.09 (s, 1H), 4.81 (s, 1H), 3.94-3.55 (m, 16H), 3.48 (t, J = 9.6 Hz, 1H), 3.29-3.27 (m, 1H). 1313C NMR (150 MHz, D2O): 151.36, 143.37, 121.20, 120.67, 101.59, 101.23, 96.33, 78.46, 75.34, 74.69, 73.51, 73.11, 72.97, 72.52, 71.53, 69.28, 69.14, 68.90, 65.51, 63.26, 62.91. HRMS (ESI) calculated value C 24 H 38 NO 16 [M+H] + :596.2191, measured value 596.2044.

[0262] Compound 54.

[0263]

[0264] EDC (0.02 mmol), HOBt (0.02 mmol), DMAP (0.02 mmol), trimethylamine (0.04 mmol) and CT (PEG) in compound 53 (0.02 mmol) in DMF (0.2 mL) 12 (0.02 mmol) was added, and the resulting solution was stirred at room temperature under nitrogen for 12 hours. The mixture was concentrated and dried under vacuum, and the crude product was purified using H2O as the eluent for Bio-Gel P-2 gel to obtain 54 (58%). 1 H NMR (600 MHz, DO): 7.03 (d, J = 9.2 Hz, 2H), 6.82 (d, J = 9.2 Hz, 2H), 5.09 (s, 1H), 4.81 (s, 1H), 3.84-3.46 (m, 65H), 3.30-3.26 (m, 1H), 2.65 (t, J = 6.5 Hz, 2H), 2.52 (s, 2H). 1313C NMR (150 MHz, D2O): 173.22, 151.36, 143.37, 121.37, 120.59, 101.20, 101.67, 97.04, 79.17, 76.06, 75.40, 75.22, 74.23, 73.69, 73.23, 72.60, 72.45, 72.22, 71.68, 71.21, 69.85, 69.61, 63.97, 38.52, 26.08. HRMS (ESI) calculated value C 51 H 90 NO 29 S[M+H] + :1212.5319, measured value 1212.5146.

[0265] Manufacture of polymer cotton.

[0266] In this embodiment, the polymerosomes of the present disclosure were prepared to encapsulate mRNA and form mRNA-polymer nanoparticles (PNPs) for delivery. The term “PNP” is used interchangeably with “polymerosomes” to describe the polymerosomes of the present disclosure. Exemplary PNPs included I2-P1 / P5 mRNA-PNP, I3-P1 / P5 mRNA-PNP, I4-P1 / P5 mRNA-PNP, I5-P1 / P5 mRNA-PNP, I6-P1 / P5 mRNA-PNP, I7-P1 / P5 mRNA-PNP, I8-P1 / P5 mRNA-PNP, I9-P1 / P5 mRNA PNP, and I10-P1 / P5 mRNA PNP, which are illustrated in FIG. 1b.

[0267] WT spike DNA construction. pMRNA XP mRNA synthesis vectors were obtained from Systems Biosciences. WT (Wuhan / WH01 / 2019 strain) spike DNA sequences with K986P and K987P mutations (2P) were codon-optimized for Homo sapiens. 1 pMRNA XPThe vector was digested with EcoRI and BamHI at 37°C for 1 hour. The DNA sequence of the spike protein was amplified using KOD One™ PCR Master Mix (Toyobo Biotechnology). The linearized pMRNAXP vector and the PCR fragment of the spike protein DNA were washed using Wizard SV Gel and the PCR Clean-Up System (Promega). The PCR fragment of the spike protein DNA was cloned into the linearized pMRNAXP vector using the In-Fusion HD Cloning Kit (Clontech Laboratories, Inc.). The cloning mixture was transformed with One Shot™ TOP10 chemically qualified E. coli (Invitrogen™) and incubated overnight at 37°C. Successful constructions were screened using Quick Taq HS DyeMix (Toyobo Biotechnology). Insertion-specific primers and backbone-specific primers were designed for colony PCR. Monoclones were selected using a pipette tip to perform PCR. The PCR products were analyzed using agarose gel electrophoresis. Possible candidates were selected and analyzed by DNA sequencing.

[0268] Synthesis of the polymer. The polymerization process was carried out according to the disclosed procedure as described in the literature [Jiaqi Fu et al., Journal of the American Chemical Society 2015 137 (37), 12153-12160] (the full text incorporated herein by reference). Modifications were made where applicable. Briefly, the stock solutions of the monomer (i.e., propagator, 2 M in DMF), initiator (50 mM in DMF, freshly prepared), terminator (iodoacetamide, 0.5 M in H2O, freshly prepared), and triethanolamine (TEOA) buffer (1 M, pH = 7.0) were prepared. The initiator was added to 80 μL of mixture buffer (DMF / TEOA = 1 / 1) and 10 μL of monomer stock solution (a v / v ratio of 1:1 was used for heteropolymers P1 / P3, P2 / P3, P1 / P4, P2 / P4, P1 / P5, and P2 / P5). Refer to Fig. 1a. After stirring for 30 minutes at room temperature, 1.9 mL of terminator stock solution was added to quench the polymerization reaction. The resulting polymer was dialyzed against H2O on the same day. The solution was freeze-dried, and the polymer was maintained at -20°C. For in vitro and in vivo experiments, the initiator was mixed with 5% IP, and the same protocol mentioned above was performed.

[0269] For the preparation of mRNA-PNP, mRNA was encapsulated within the corresponding polymer using a self-assembly process; that is, a polymer in ethanol (10 mg / mL) was mixed with an aqueous solution of mRNA (1 mg / mL) at pH 4.0 in a 3 to 1 N / P ratio. Refer to Fig. 1b. mRNA-PNP was dialyzed against PBS buffer (pH 7.4) overnight at 4°C using a Micro Float-A-Lyzer (10 kDa MWCO, Spectrum Laboratories) and stored at -40°C until further use.

[0270] Characterization of polymerosomes. To investigate the morphology of mRNA-polymer complexes, the inventors first mixed a P1 polymer with mRNA, which was found to form nearly spherical nanoparticles. The complex of the P1 / P5 copolymer and mRNA was liposome-like. The polymer may form a positively charged layer, which can encapsulate the mRNA and facilitate subsequent cellular uptake through the binding of zwitterions.

[0271] Molecular weight and polymerization index were characterized by gel permeation chromatography (GPC). The polymer exhibited a single-mode but somewhat broad molecular weight distribution in the GPC chromatogram and eluted at a relatively low elution time, which indicates its polymeric state. The peak molecular weight was 10.2 kDa (PDI = 1.33) for mRNA-PNP (P1 / P5).

[0272] Example 2: Encapsulation and Transfection Efficiency of Polymer Somes

[0273] To identify the optimal polymer for efficient intracellular delivery of GFP-mRNA as a model, homopolymers and heteropolymers were synthesized by copolymerizing different propagators, and their encapsulation ability and transfection efficiency in HEK293T cells were evaluated.

[0274] Quantification of encapsulated mRNA.

[0275] Encapsulation efficiency was determined using the Quant-iT™ RiboGreen™ RNA reagent and kit (Thermo Scientific™). The prepared mRNA polymerosomes (mRNA-PNP) were treated overnight with 10 mM GSH. Subsequently, the solution was diluted 250-fold with 1X TE buffer and further diluted 2-fold with TE buffer or TE buffer containing 2% Triton X-100. Standard curves were established by preparing mRNA at concentrations of 100, 50, 25, 12.5, and 0 ng / ml in TE or TE buffer containing 1% Triton X-100. After incubation at 37°C for 10 minutes, the Quant-iT™ RiboGreen™ RNA reagent was added to the wells. Fluorescence intensity was measured using a Clariostar® Plus (BMG LabTech).

[0276] Results. All copolymers containing guanidine groups were able to encapsulate GFP-mRNA. In particular, I1-P2 / P3, I1-P2 / P4, and I1-P2 / P5 copolymers having a trivalent guanidine moiety exhibited a higher ability to encapsulate mRNA and were comparable to the results obtained using the traditional transfection agent polyethyleneimine (PEI). Refer to Figure 2a.

[0277] Formulation of WT spike mRNA to form mRNA-PNP. To obtain WT spike mRNA, linear DNA containing a T7 promoter, 50 non-translating regions, 30 non-translating regions, S-2P, and a poly(A)-tail signal sequence was amplified using TOOLS Ultra-High-Faith DNA Polymerase (BioTools Company, Limited) with 1 μL of DNA template in the mMESSAGE mMACHINE™ Kit (Thermo Scientific) for 1 hour at 37°C according to the manufacturer's protocol. The mRNA was purified using the RNA Cleanup Kit (BioLabs) according to the manufacturer's protocol and stored at -80°C until further use. For the formulation of mRNA-PNP, the mRNA was encapsulated within the corresponding polymer using a self-assembly process; that is, a polymer in ethanol (10 mg / mL) was mixed with an aqueous solution of mRNA (1 mg / mL) at pH 4.0 at different N / P ratios. mRNA-PNP was dialyzed against PBS buffer (pH 7.4) overnight at 4°C using a microfloat-A-riser (10 kDa MWCO, Spectrum Laboratory) and stored at -40°C until further use.

[0278] Results. The results showed that the P1 / P5 copolymer exhibited excellent ability to capture spike mRNA at N / P ratios of 1, 5, 10, or 20 (Fig. 3a), and that the average particle size of the generated mRNA-P1 / P5 copolymer complex was approximately 127 nm, as revealed by cryo-EM, TEM, and dynamic light scattering (DLS) analyses (Fig. 3b). The measured zeta potential was approximately -4.2 mV. An N / P ratio of 3 was selected for the following experiments to ensure complete encapsulation. The release and translation of mRNA can be attributed to GSH-mediated polymerase chain degradation, as this occurs in a time-dependent manner in the presence of 10 mM GSH (data not presented).

[0279] HEK293T cell transfection.

[0280] Transfection of polymerosomes encapsulating GFP-mRNA. Subsequently, the inventors evaluated the transfection efficiency of GFP-mRNA in HEK293T cells by using different copolymers. HEK293T cells were placed in 6-well plates in 2.5 mL of DMEM medium at a rate of 5 x 10⁴ per well. 5 Cells were plated. 1 μg of GFP mRNA or 3 μg of WT spike mRNA was formulated with the corresponding polymer according to the procedure mentioned above and then added to the cells. 18 hours after transfection, GFP and spike expression were monitored by fluorescence microscopy and Western blotting, respectively. For WB, cells containing spike protein were lysed in 200 μL of RIPA lysis buffer containing a protease inhibitor and incubated for 10 minutes. Subsequently, the cells were vortexed, centrifuged, and analyzed by Western blotting using a polyclonal anti-SARS-CoV-2 S protein antibody (1:5000, containing 1% BSA), followed by an HRP-conjugated anti-rabbit antibody (1:10000). Spike protein was detected by a chemiluminescent HRP substrate and visualized by a trans-illuminator (Fujifilm LAS3000).

[0281] Results. The results showed that copolymer P1 exhibited HEK293T cell transfection ability comparable to the traditional transfector polyethyleneimine (PEI), whereas the heteropolymers P1 / P4, P2 / P4, P1 / P5, and P2 / P5 demonstrated superior transfection efficiency and were able to release mRNA for translation into GFP. In particular, the polymers containing zwitterionic groups, P1 / P5 and P2 / P5 (Fig. 2b), were highly effective, likely due to membrane fusion as described above. All tested polymerosomes showed less effect on cell viability than the traditional transfector PEI and did not exhibit apparent cytotoxicity (data not shown).

[0282] Transfection of polymerosomes encapsulating WT spike mRNA. Subsequently, the inventors transfected HEK293T cells with a spike mRNA-P1 / P5 complex (3 μg) and performed Western blotting. 48 hours after transfection, the cells were analyzed for spike protein translation by Western blotting with a spike-specific antibody. A significant band at ~250 kDa corresponding to the SARS-CoV-2 spike protein was observed (Lane 2) compared to spike mRNA as a negative control (Lane 1) (Fig. 3c). This study confirmed that the P1 / P5 copolymer is an effective nanocarrier for in vitro mRNA transfection.

[0283] Location of mRNA-PNP within the cell.

[0284] To visualize the localization of mRNA-PNP within cells, FITC-labeled polymers were synthesized from P1 / P4 / P5, where FITC was conjugated to the polymer via amine groups on P4. As shown in Figure 4, the co-localization of mRNA-PNP (I1-P1 / P4 / P5) with lysosomes was lower than that of mRNA-PNP (I1-P1 / P4), indicating that alkylated zwitterion residues can significantly improve membrane fusion and lysosome escape.

[0285] Example 3: Targeted (Selective) Delivery

[0286] To selectively deliver the mRNA vaccine to antigen-presenting cells (APCs), particularly dendritic cells, the inventors designed an initiator having different glycan heads recognized by lectin receptors, such as Siglec-1, Siglec-2, Siglec-5 / E, and DC-SIGN, which are predominantly expressed on DCs and macrophages. To evaluate mRNA-PNP uptake via Siglec, the inventors compared the binding and internalization of mRNA-PNP into T cells, B cells, and bone marrow-derived dendritic cells (BMDCs).

[0287] method

[0288] Splenocyte preparation and BMDC culture. To prepare splenocytes, mouse spleens were homogenized with the frozen ends of glass slides, treated with RBC lysis buffer (Sigma) to deplete red blood cells (RBCs), and then passed through a cell strainer (BD Biosciences). Bone marrow-derived dendritic cells (BMDCs) were prepared as described. 3Briefly, bone marrow was isolated from mouse femurs and tibias and treated with RBC lysis buffer (Sigma-Aldrich) to deplete RBCs. Subsequently, cells were cultured at a density of 2 x 10⁵ cells / ml in RPMI-1640 containing 10% heat-inactivated FBS (Thermo Fisher Scientific), 1% penicillin / streptomycin (Thermo Fisher Scientific), 50 μM 2-mercaptoethanol (Thermo Fisher Scientific), and 20 ng / ml recombinant mouse GM-CSF (Ebioscience). On the 3rd day, the cells were supplemented with an equivalent volume of the complete culture medium described above, and on the 6th day, half the volume of medium was supplied fresh. On the 8th day, the suspended cells were collected.

[0289] Treatment of splenocytes and BMDCs with PNP. Splenocytes or BMDCs were incubated with 1:2000 mRNA-PNP (diluted to 10 mg / mL) in RPMI-1640 at 37°C for 24 hours. Cells were blocked with an Fc receptor binding inhibitor (clone: ​​93, eBioSciences) for 20 minutes. Splenocytes were stained with antibodies against CD3 (clone: ​​17A2, BV421-conjugated, BioLegend) and CD19 (clone: ​​1D3, PECy7-conjugated, BD BioSciences). BMDCs were stained with an antibody against CD11c (clone: ​​N418 APC-conjugated, BioLegend). Labeled cells were analyzed using FACSC and a flow cytometer (BD BioSciences).

[0290] C2C12 cell culture. Mouse muscle myoblast cell line C2C12 was purchased from the National Institute of Biological Resources Collection and Research in Taiwan. C2C12 cells were cultured in high-glucose (ATCC) DMEM supplemented with 10% FBS and 1 x antibiotic-antifungal agent. Cells were incubated at 37°C with a 5% CO2 and humidified atmosphere control. The culture medium was replaced every 2 to 3 days.

[0291] Treatment of C2C12 with polymerosomes. Cultured C2C12 myoblasts were detached from culture dishes using 0.25% trypsin-EDTA (Gibco) and neutralized with growth medium containing 10% FBS. mRNA-PNP (I1-P1 / P4-FITC-P5) or mRNA-PNP (I9-P1 / P4-FITC / P5) was added to 200 μL of C2C12 cells (2 x 10⁶) in growth medium. 5 It was added to cells to reach final dilutions of 1:1000, 1:2000, 1:4000, or 1:8000 relative to the original stock (10 mg / mL). Three time points were measured: 5 minutes, 1 hour, and 24 hours.

[0292] Flow cytometry. After incubation with mRNA-PNP, BMDC cells were washed with ice-cold FACS buffer (1% FBS in 1 x DPBS containing 0.1% sodium azide), incubated on ice with purified anti-mouse CD16 / 32 antibody (BioLegend) in FACS buffer for 20 minutes, and then washed with FACS buffer. BMDCs were stained with APC anti-mouse CD11c antibody (BioLegend) at 4°C for 30 minutes and washed with FACS buffer. Finally, BMDCs were stained with propidium iodide (Sigma-Aldrich). C2C12 cells were centrifuged and washed with FACS buffer. Cells were stained with propidium iodide. Flow cytometry was performed on a FACSCanto flow cytometer (BD Biosciences).

[0293] Glycan-PNP and DC-SIGN binding assay via ELISA. To evaluate the binding of DC-SIGN to mannosid-modified PNPs, ELISA plates were coated overnight at 4°C with mRNA-PNP (I5-P1 / P5), mRNA-PNP (I6-P1 / P5), mRNA-PNP (I7-P1 / P5), mRNA-PNP (I8-P1 / P5), mRNA-PNP (I9-P1 / P5), or mRNA-PNP (I10-P1 / P5) (10 mg / mL) in PBS, respectively. The plates were incubated at room temperature for 1 hour at pH 7.4, 6.0, and 5.0 with diluted DC-SIGN ECD (15 to 0.075 nM in HEPES buffer containing 20 mM HEPES, 150 mM NaCl, 10 mM CaCl2, and 0.1% BSA). Conjugated DC-SIGN ECD was detected using an HRP-conjugated anti-DC-SIGN (B2) IgG antibody (Santa Cruz Biotechnology). After incubation at room temperature for 1 hour, the plates were treated with tetramethylbenzidine (TMB) for 10 minutes. After adding 0.5 M sulfuric acid to the plates using a microplate reader, the optical density was measured at 450 nm. Apparent Kd was calculated using a nonlinear regression curve fit for total binding with a graphpad prism.

[0294] Glycan-PNP binding assay for DC-SIGN-Fc, MMR-Fc, MINCLE-Fc, Dectin-2-Fc, and Langerin-Fc via ELISA. To evaluate the binding of receptor proteins to mannosid-modified PNPs, ELISA plates were coated overnight at 4°C with mRNA-PNP (I1-P1 / P5), mRNA-PNP (I8-P1 / P5), mRNA-PNP (I9-P1 / P5), or mRNA-PNP (I10-P1 / P5) (10 mg / mL) in PBS, respectively. The plates were incubated at room temperature for 1 hour at pH 7.4 with diluted DC-SIGN-Fc, MMR-Fc, MINCLE-Fc, Dectin-2-Fc, and Langerin-Fc (0.625 μg / mL in buffer). The bound protein was detected using an HRP-conjugated anti-Fc IgG antibody. After incubation at room temperature for 1 hour, the plate was treated with tetramethylbenzidine (TMB) for 10 minutes. After adding 0.5 M sulfuric acid to the plate using a microplate reader, the average optical density was measured at 450 nm.

[0295] result

[0296] As evaluated by flow cytometry, FITC-conjugated mRNA-PNPs were incubated with each cell line for 1 hour. I2 mRNA-PNPs containing 9BPCNeu5Ac-conjugated N-glycans intended to target Siglec-2 exhibited higher cellular uptake by all APCs compared to I1 mRNA-PNPs without glycan modification (Fig. 5). Specifically, in this experiment, compared to I1 polymerosomes, I2 polymerosomes showed increases of 33.1%, 32.6%, and 27.8% in BMDC, B cell, and T cell uptake, respectively. Similar results were obtained by targeting Siglec-5 / E and Siglec-1 using I3 and I4 mRNA-PNPs, respectively, where all-glycan-decorated polymerosomes exhibited superior uptake by all APCs compared to glycan-free mRNA-PNPs. Similarly, I9-P1 / P4-FITC / P5 mRNA-PNP showed higher (about 1x higher, Fig. 9) uptake by C2C12 muscle cells compared to I1-P1 / P4-FITC-P5 mRNA-PNP.

[0297] As shown in Figure 6, I5 polymerosomes with aryl mannose heads (I5-P1 / P4-FITC / P5) showed approximately 34% higher cellular uptake by BMDCs compared to I1 polymerosomes without glycan heads (I1-P1 / P4-FITC / P5) (33.8% increase). On the other hand, B cells and T cells with insignificant DC-SIGN expression showed only a slight increase in fluorescence signal (16.2% increase and 12.8% increase, respectively) when treated with polymerosomes. These data demonstrated that efficient internalization and selective uptake of mRNA-PNP (I5-P1 / P4-FITC / P5) by dendritic cells can be achieved through DC-SIGN receptor targeting.

[0298] Evaluation of DC-SIGN binding to mRNA-polymerosomes generated from I5-P1 / P5, I6-P1 / P5, I7-P1 / P5, I8-P1 / P5, I9-P1 / P5, and I10-P1 / P5 under different pH values ​​indicates that these polymerosomes have low K D It was shown that they can bind to DC-SIGN (Table 1). mRNA-polymerosomes from I5-P1 / P5, I8-P1 / P5, I9-P1 / P5, and I10-P1 / P5 bind to the DC-SIGN extracellular domain (ECD) with nearly the same affinity at pH 7.4 and 5.0. In comparison, binding of mRNA-polymerosomes from I6-P1 / P5 and I7-P1 / P5 was not detected at lower pH values, which suggests that coordination for calcium ions decreases at lower pH values.

[0299] Table 1

[0300]

[0301] While I do not wish to be bound by theory, these binding results indicate that aryl trimannosides interact with DC-SIGN in the acidic endosome compartment. This binding stability would enhance DC-SIGN-mediated signaling and its synergy with endosome-resident Toll-like receptors, such as TLR7. The strong binding of aryl trimannosides and PNPs to DC-SIGN may be due to the dense display of the ligands, and the aryl groups may be involved in CH-π and hydrophobic interactions. Furthermore, for receptor-targeted delivery, ligands are typically linked to carriers, and the distance between the carrier and the ligand is regulated by the presence of spacers. mRNA-PNPs accompanied by longer ligands (I8-P1 / P5 with Man-Ar-PEG12 and I7-P1 / P5 with Man-PEG12) exhibited slightly higher affinity for DC-SIGN. Overall, mRNA-PNP (I9-P1 / P5) with aryl-trimannosides exhibited the highest affinity and lowest KD for DC-SIGN. The increased affinity may be due to the clustering effect and spatial arrangement of ligands in the polymer, and the aryl moiety may facilitate its hydrophobic interactions.

[0302] To investigate whether the uptake of mannosylated mRNA-PNP depends on DC-SIGN, additional binding affinities were performed for DC-SIGN, macrophage mannose receptor (MMR), MINCLE, Dectin-2, and Langerin. As shown in Figure 7, all exhibited selective binding compared to I1, I8, I9, and I10 polymerosomes. Among these, the branched type of aryl-trimannoside I9 showed a superior preference for DC-SIGN compared to the linear type of aryl-trimannoside I10. The fact that I9 presented more selective binding to DC-SIGN supported the possibility that the efficient uptake of mRNA-I9-P1 / P5 by DCs is more likely mediated by DC-SIGN.

[0303] Example 4: Immunization using the polymer somta of the present disclosure

[0304] Next, the inventors evaluated the effects of WT spike mRNA-PNP with or without an aryl mannosid head on vaccination and immune response.

[0305] Method and Immunization Design.

[0306] Animals. Balb / c mice (8 weeks) were purchased from the National Laboratory Animal Center in Taiwan. All mice were maintained in a specific pathogen-free environment. 8-week-old Balb / c mice were immunized twice at 2-week intervals. Each vaccination contained PBS (100 μl). Serum collected from immunized mice was applied to the ELISA assay 10 days after the last immunization. The experimental protocol was approved by the Animal Ethics Committee of Academia Sinica (Approval No. 22-08-1901).

[0307] Animal Immunization. 6 to 8-week-old BALB / c mice (n = 5) were intramuscularly immunized with 15 μg of mRNA-PNP in phosphate-buffered saline (PBS). Animals were immunized at week 0, boosted with a second vaccination at week 2 (Fig. 8a), and serum samples were collected from each mouse 1 week after the second immunization. As a positive control, a group treated with spike mRNA-LNP (including ALC-0315, DSPC, ALC-0159, and cholesterol, which are commonly used in current mRNA vaccine formulations) was included.

[0308] Measurement of serum IgG titers. IgG titers in mouse serum were determined using ELISA. Wells of a 96-well ELISA plate (Grainer Bio-One) were coated overnight at 4°C with 100 ng SARS-CoV-2 spike protein (AcroBioSystems) in 100 mM sodium bicarbonate at pH 8.8. The wells were blocked with 200 μl 5% skim milk in 1X PBS for 1 hour at 37°C and washed three times with 200 μl PBST (1X PBS, 0.05% Tween 20, pH 7.4). Mouse serum samples with 2-fold serial dilutions were added to the wells for incubation at 37°C for 2 hours and washed six times with 200 μl PBST. The wells were incubated with 100 μl of HRP-conjugated anti-mouse secondary antibody (1:10000 in PBS) at 37°C for 1 hour and washed 6 times with 200 μl of PBST. 100 μl of horseradish peroxidase substrate (1-Step™ Ultra TMB-ELISA substrate solution) (Thermo Scientific™) was added to the wells, followed by the addition of 100 μl of 1 M H2SO4. After incubation for 30 minutes, the absorbance (OD 450 nm) was measured using a Spectramax M5.

[0309] Pseudovirus Neutralization Assay. Pseudoviruses were constructed using the RNAi Core Facility of Academia Sinica using a procedure similar to that previously described. Briefly, SARS-CoV-2 spike protein-bearing morphological lentiviruses were generated by transiently transfecting HEK-293T cells with pCMV-ΔR8.91, pLAS2w.Fluc.Ppuro. HEK-293T cells were seeded 1 day prior to transfection, and the specified plasmid was delivered into the cells using the transITR-LT1 transfection reagent (Mirus). Fresh culture medium was supplied at 16 hours, and cells were collected at 48 and 72 hours after transfection. Cell debris was removed by centrifugation at 4,000 xg for 10 minutes, and the supernatant was passed through a 0.45-μm syringe filter (Pol Corporation). Pseudotyped lentiviruses were aliquoted and stored at -80°C. To estimate lentivirus titers by the AlamaBlue assay (Thermo Scientific), transduction units (TU) of SARS-CoV-2 pseudotyped lentivirus were estimated using a cell viability assay in response to the limiting dilution of the lentivirus. Briefly, HEK-293T cells stably expressing the human ACE2 gene were plated on 96-well plates one day prior to lentivirus transduction. To titrate the pseudotyped lentivirus, different amounts of lentivirus were added to culture medium containing polybrene (final concentration 8 μg / ml). Spin infection was performed at 1,100 xg in 96-well plates for 30 minutes at 37°C. After incubating cells at 37°C for 16 hours, the culture medium containing the virus and polybrene was removed and replaced with fresh, whole DMEM containing 2.5 μg / ml puromycin. After treating with puromycin for 48 hours, the culture medium was removed, and cell viability was detected using 10% Alamar Blue reagent according to the manufacturer's instructions.The viability of uninfected cells (no puromycin treatment) was set to 100%. Viral titer (transduction unit) was determined by plotting the diluted viral dose against the viable cells. For the neutralization assay, heat-inactivated serum or antibodies were serially diluted and incubated with 1,000 TU of SARS-CoV-2 pseudotype lentivirus in DMEM at 37°C for 1 hour. Subsequently, the mixture was seeded into 10,000 HEK-293T cells stably expressing the human ACE2 gene in 96-well plates. The culture medium was replaced with fresh, complete DMEM (supplemented with 10% FBS and 100 U / mL penicillin / streptomycin) 16 hours after infection, and the cells were cultured continuously for an additional 48 hours. The expression levels of the luciferase gene were determined using the Bright-Glo Luciferase Assay System (Promega). The relative optical unit (RLU) was detected by the Tekhan i-control (Infinite 500). The suppression percentage is given by Equation (RLU. 대조군 - RLU 혈청 It was calculated as the ratio of the decrease in RLU in the presence of diluted serum to the RLU value of the control without serum using the ) / RLU control.

[0310] result

[0311] The results showed that both I1-P1 / P5 polymerosome treatment and mRNA-LNP treatment could generate levels of 10,000 anti-spike antibodies in serum on day 28. In contrast, I9-P1 / P5 polymerosome treatment was able to generate levels of approximately 30,000 anti-spike antibodies, which was at least three times higher (Fig. 8b). Subsequently, the serum was tested for its ability to neutralize pseudovirus-mediated entry into ACE2-expressing cells. Antiserum levels from I1-P1 / P5 polymerosome were similar to those of the mRNA-LNP group; both were less than 2,000. By comparison, significantly higher levels of neutralizing antibodies (greater than 6,000) were observed in the I9-P1 / P5 polymerosome group (Fig. 8c), and spike-specific antibody titers and pseudovirus neutralizing activity were well correlated.

[0312] Exemplary embodiment

[0313] Embodiment 1. A copolymer for forming a polymer some, wherein the copolymer comprises: an initiator block comprising a glycan head; a propagator block comprising a functional moiety comprising a guanidine group, a zwitterion group, a diethylenetriamine, or a combination thereof; and a link jointly connecting the initiator block and the propagator block, wherein the link comprises a disulfide bond.

[0314] Embodiment 2. A copolymer according to Embodiment 1, wherein the glycan head comprises a terminal mannoside.

[0315] Embodiment 3. A copolymer comprising an O-aryl mannoside comprising a benzene ring in which the glycan head is optionally substituted, in Embodiment 1 or Embodiment 2.

[0316] Embodiment 4. A copolymer in any one of Embodiments 1 to 3, wherein the glycan head comprises a mono-mannosid, a di-mannosid, or a tri-mannosid.

[0317] Embodiment 5. A copolymer according to Embodiment 4, wherein the tri-mannosid is a linear or branched tri-mannosid.

[0318] Embodiment 6. A copolymer according to Embodiment 5, wherein the branched tri-mannosid is α-1,3-α-1,6-trimannosid.

[0319] Embodiment 7. A copolymer in any one of Embodiments 1 to 6, wherein the initiator block further comprises an initiator spacer.

[0320] Embodiment 8. A copolymer according to Embodiment 7, wherein the initiator spacer comprises a saturated carbon moiety, a polyethylene glycol (PEG) moiety, or a combination thereof.

[0321] Embodiment 9. A copolymer according to Embodiment 8, wherein the saturated carbon moiety comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 carbons (optional, 2 to 6 carbons).

[0322] Embodiment 10. A copolymer according to Embodiment 8 or Embodiment 9, wherein the PEG moiety comprises 2 to 72 (OCH2CH2) subunits.

[0323] Embodiment 11. A copolymer in which the PEG moiety of Embodiment 10 is linear, branched, or morphologically coordinated.

[0324] Embodiment 12. A copolymer configured such that the glycan head binds to a dendritic cell in any one of Embodiments 1 to 11.

[0325] Embodiment 13. A copolymer according to Embodiment 12, wherein the glycan head is configured to selectively bind to the DC-SIGN.

[0326] Embodiment 14. In Embodiment 13, the glycan head is K in the range of 5 to 8000 nM at pH 7.4. D A copolymer configured to bond to a DC-SIGN.

[0327] Embodiment 15. In Embodiment 14, K D A copolymer in the range of 5 to 500 nM at pH 7.4.

[0328] Embodiment 16. In any one of Embodiments 13 to 15, the glycan head is K in the range of 1 to 2000 nM at pH 5. D A copolymer configured to bond to a DC-SIGN.

[0329] Embodiment 17. In Embodiment 16, K D A copolymer in the range of 1 to 600 nM at pH 5.

[0330] Embodiment 18. In Embodiment 1, the glycan head is 9 BPC Neu5Ac conjugated N-glycan, Neu5Ac conjugated N-glycan, 9 TCC A copolymer comprising a Neu5Ac conjugated N-glycan or a combination thereof.

[0331] Embodiment 19. A copolymer according to Embodiment 18, wherein the initiator block is configured to bond to Siglec-2, Siglec-5 / E, Siglec-1, or a combination thereof.

[0332] Embodiment 20. A copolymer in any one of Embodiments 1 to 19, wherein the initiator block is selected from the group consisting of the following:

[0333]

[0334] Here, the filled circle represents the mannosid, the empty circle represents the galactose, the filled square represents the GlcNAc, and the diamond represents the Neu5Ac.

[0335] Embodiment 21. A copolymer in any one of Embodiments 1 to 20, wherein the propagator block comprises more than one guanidine group.

[0336] Embodiment 22. A copolymer according to Embodiment 21, wherein the propagator block comprises three guanidine groups.

[0337] Embodiment 23. A copolymer in any one of Embodiments 1 to 22, wherein the propagator block comprises a propagator spacer comprising a saturated carbon moiety, a polyethylene glycol (PEG) moiety, or a combination thereof.

[0338] Embodiment 24. A copolymer according to Embodiment 23, wherein the saturated carbon moiety comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 carbons (optional, 2 to 6 carbons).

[0339] Embodiment 25. A copolymer according to Embodiment 23 or Embodiment 24, wherein the PEG moiety comprises 2 to 72 (OCH2CH2) subunits.

[0340] Embodiment 26. A copolymer in which the PEG moiety of Embodiment 25 is linear, branched, or morphologically coordinated.

[0341] Embodiment 27. A copolymer in any one of embodiments 1 to 26, comprising a plurality of propagator blocks and a plurality of connections, wherein each of the propagator blocks is connected to at least another propagator block or initiator block of the propagator blocks through one of the plurality of connections.

[0342] Embodiment 28. Any one of Embodiments 1 to 27, wherein the propagator block is a first propagator block, the linkage is a first linkage, and the copolymer further comprises a second propagator block connected to the first propagator block through a second linkage; wherein the first propagator block and the second propagator block independently comprise a guanidine group, a zwitterion group, a diethylenetriamine, or a combination thereof; and the second linkage comprises a disulfide bond.

[0343] Embodiment 29. A copolymer according to Embodiment 28, wherein the first propagator block comprises a guanidine group and the second propagator block comprises a zwitterion group.

[0344] Embodiment 30. A copolymer according to Embodiment 28, wherein the first propagator block comprises a guanidine group and the second propagator block comprises diethylenetriamine.

[0345] Embodiment 31. Any one of Embodiments 28 to 30, wherein the copolymer further comprises a third propagator block, wherein the third propagator block is connected to the first propagator block or the second propagator block through a third link comprising a disulfide bond.

[0346] Embodiment 32. A copolymer in any one of Embodiments 1 to 31, wherein the propagator block is selected from the group consisting of the following:

[0347]

[0348]

[0349] Embodiment 33. The copolymer of Embodiment 32, comprising at least two propagator blocks, wherein the at least two propagator blocks are (1) PB1 and PB5, (2) PB1 and PB4, (3) PB2 and PB5, (4) PB2 and PB5, or (5) P1, P4 and P5.

[0350] Embodiment 34. In Embodiment 33, the initiator block and at least two propagator blocks are IB5-PB1 / PB5, IB5-PB1 / PB4, IB5-PB2 / PB5, IB5-PB2 / PB4, IB5-PB1 / PB4 / PB5, IB6-PB1 / PB5, IB6-PB1 / PB4, IB6-PB2 / PB5, IB6-PB2 / PB4, IB6-PB1 / PB4 / PB5, IB7-PB1 / PB5, IB7-PB1 / PB4, IB7-PB2 / PB5, IB7-PB2 / PB4, IB7-PB1 / PB4 / PB5, IB8-PB1 / PB5, IB8-PB1 / PB4, A copolymer selected from the group consisting of IB8-PB2 / PB5, IB8-PB2 / PB4, IB8-PB1 / PB4 / PB5, IB9-PB1 / PB5, IB9-PB1 / PB4, IB9-PB2 / PB5, IB9-PB2 / PB4, IB9-PB1 / PB4 / PB5, IB10-PB1 / PB5, IB10-PB1 / PB4, IB10-PB2 / PB5, IB10-PB2 / PB4 and IB10-PB1 / PB4 / PB5.

[0351] Embodiment 35. A polymer swab comprising a membrane defining an internal space, wherein the membrane comprises a copolymer of any one of Embodiments 1 to 34.

[0352] Embodiment 36. The polymer filament of Embodiment 35, wherein the copolymer occupies at least 50%, 70%, 80%, 90%, 95%, or 99% of the membrane.

[0353] Embodiment 37. The polymer filament of Embodiment 35 or Embodiment 36, wherein the membrane encapsulates a payload therein.

[0354] Embodiment 38. The polymerosome of Embodiment 37, wherein the payload is a nucleic acid, compound, polypeptide, protein, glycan, or a combination thereof.

[0355] Embodiment 39. The polymerosome of Embodiment 38, wherein the nucleic acid is RNA or DNA.

[0356] Embodiment 40. The polymerosome of Embodiment 39, wherein the payload codes for a polypeptide.

[0357] Embodiment 41. A polymerosome in any one of embodiments 37 to 40, wherein the payload is immunogenic or the payload is a nucleic acid configured to code for an immunogenic polypeptide or protein.

[0358] Embodiment 42. A polymer filament in any one of embodiments 35 to 41, wherein the copolymer is a first copolymer and the membrane further comprises a second copolymer, wherein the first copolymer and the second copolymer are independent of any one of embodiments 1 to 34.

[0359] Embodiment 43. In any one of embodiments 35 to 42, a polymer wool having a diameter of 0.001 to 5 micrometers or 0.01 to 5 micrometers.

[0360] Embodiment 44. A polymer somt in any one of embodiments 35 to 43, wherein the payload is a first payload and the membrane further encapsulates a second payload.

[0361] Embodiment 45. The polymerosome in Embodiment 44, wherein the second payload is a nucleic acid, compound, polypeptide, protein, glycan, or a combination thereof.

[0362] Embodiment 46. A polymer wool according to Embodiment 45, wherein the first payload and the second payload are different.

[0363] Embodiment 47. A formulation comprising any one of the polymer filaments of Embodiments 35 to 46.

[0364] Embodiment 48. The formulation of Embodiment 47 comprising 0.01 to 95% (w / w) of polymer cotton.

[0365] Embodiment 49. A formulation according to Embodiment 47 or Embodiment 48, wherein the polymer wool is the first polymer wool and the composition further comprises the second polymer wool.

[0366] Embodiment 50. The formulation of Embodiment 49, wherein the first polymer swab and the second polymer swab differ in size, the copolymer forming the membrane, the payload encapsulated within the polymer swab, or a combination thereof.

[0367] Embodiment 51. A formulation comprising, in any one of Embodiments 47 to 50, a pharmaceutically acceptable excipient, ajuvant, or a combination thereof.

[0368] Embodiment 52. The formulation of claim 51, wherein the excipient comprises a solvent, dispersion medium, diluent, dispersant, suspension aid, surfactant, isotonic agent, thickener or emulsifier, preservative, polymer, peptide, protein, cell, hyaluronidase, or a mixture thereof.

[0369] Embodiment 53. A formulation according to Embodiment 51 or Embodiment 52 in which the ajuvant comprises C34, gluco-C34, 7DW8-5, C17, C23, C30, α-galactosylceramide, aluminum salt, squalene, MF59, or QS-21. Other examples of ajuvants in some vaccines that may be used in the composition of the present disclosure are aluminum hydroxide, aluminum phosphate, alum (potassium aluminum sulfate), mixed aluminum salts, Freund complete ajuvant, Freund incomplete ajuvant, AS03, MF59, and CpG 1018, or combinations thereof.

[0370] Embodiment 54. A kit for manufacturing a polymer some, comprising: a first reagent comprising an initiator, wherein the initiator comprises a glycan head and an initiator linkage moiety; and a second reagent comprising a propagator, wherein the propagator comprises a functional moiety and a propagator linkage moiety, wherein the functional moiety comprises a guanidine group, a zwitterion group, a diethylenetriamine, or a combination thereof; wherein the initiator linkage moiety is configured to be coupled to the propagator linkage moiety through a linkage comprising a disulfide bond.

[0371] Embodiment 55. The kit of Embodiment 54, wherein the glycan head comprises a terminal mannoside.

[0372] Embodiment 56. A kit according to Embodiment 54 or Embodiment 55, wherein the glycan head comprises an O-aryl mannoside.

[0373] Embodiment 57. A kit in any one of embodiments 54 to 56, wherein the glycan head comprises a mono-mannosid, a di-mannosid, or a tri-mannosid.

[0374] Embodiment 58. The kit of Embodiment 57, wherein the tree-mannosid is a linear or branched tree-mannosid.

[0375] Embodiment 59. The kit of Embodiment 58, wherein the branched tri-mannosid is α-1,3-α-1,6-trimannosid.

[0376] Embodiment 60. A kit in any one of embodiments 54 to 59, wherein the initiator further comprises an initiator spacer comprising a saturated carbon moiety, a polyethylene glycol (PEG) moiety, or a combination thereof.

[0377] Embodiment 61. The kit of Embodiment 60, wherein the saturated carbon moiety comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 carbons (optional, 2 to 6 carbons).

[0378] Embodiment 62. The kit of Embodiment 61, wherein the PEG moiety comprises 2 to 72 (OCH2CH2) subunits.

[0379] Embodiment 63. The kit of Embodiment 62, wherein the PEG moiety is linear, branched, or stellately coordinated.

[0380] Embodiment 64. A kit configured such that the glycan head binds to a dendritic cell in any one of embodiments 54 to 63.

[0381] Embodiment 65. A kit according to Embodiment 64, wherein the glycan head is configured to selectively bind to the DC-SIGN.

[0382] Embodiment 66. In Embodiment 65, the glycan head is K in the range of 5 to 8000 nM at pH 7.4. D A kit configured to be coupled to a DC-SIGN.

[0383] Embodiment 67. In Embodiment 66, K D A kit with a pH of 7.4 and a range of 5 to 500 nM.

[0384] Embodiment 68. In any one of embodiments 65 to 67, the glycan head is K in the range of 1 to 800 nM at pH 5. D A kit configured to be coupled to a DC-SIGN.

[0385] Embodiment 69. In Embodiment 68, K D A kit with a pH of 5 and a range of 1 to 600 nM.

[0386] Embodiment 70. In any one of embodiments 54 to 69, the glycan head is 9 BPC Neu5Ac conjugated N-glycan (I2), Neu5Ac conjugated N-glycan (I3), 9 TCC A kit comprising a Neu5Ac conjugated N-glycan (I4) or a combination thereof.

[0387] Embodiment 71. A kit according to Embodiment 70, wherein the glycan head is configured to bind to Siglec-2, Siglec-5 / E, Siglec-1, or a combination thereof.

[0388] Embodiment 72. In any one of Embodiments 54 to 71, the kit in which the initiator-linking moiety is a thiol group or a dithiolan group.

[0389] Embodiment 73. A kit selected from the group consisting of the following by the initiator in any one of embodiments 54 to 72:

[0390]

[0391]

[0392] Embodiment 74. A kit in any one of embodiments 54 to 73, wherein the propagator comprises more than one guanidine group.

[0393] Embodiment 75. A kit according to Embodiment 74, wherein the propagator comprises three guanidine groups.

[0394] Embodiment 76. A kit in any one of embodiments 54 to 75, wherein the propagator further comprises a propagator spacer comprising a saturated carbon moiety, a polyethylene glycol (PEG) moiety, or a combination thereof.

[0395] Embodiment 77. The kit of Embodiment 76, wherein the saturated carbon moiety comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 carbons (optional, 2 to 6 carbons).

[0396] Embodiment 78. A kit according to Embodiment 76 or Embodiment 77, wherein the PEG moiety comprises 2 to 72 (OCH2CH2) subunits.

[0397] Embodiment 79. The kit of Embodiment 78, wherein the PEG moiety is linear PEG.

[0398] Embodiment 80. Any one of embodiments 54 to 79, wherein the propagator of the second reagent is the first propagator, and the second reagent further comprises the second propagator, or the kit further comprises the third reagent comprising the second propagator; wherein the first propagator and the second propagator independently comprise a functional moiety comprising a guanidine group, a zwitterion group, diethylenetriamine, or a combination thereof.

[0399] Embodiment 81. A kit according to Embodiment 80, wherein the first propagator comprises a guanidine group and the second propagator comprises a zwitterion group.

[0400] Embodiment 82. A kit according to Embodiment 80, wherein the first propagator comprises a guanidine group and the second propagator comprises diethylenetriamine.

[0401] Embodiment 83. In any one of Embodiments 54 to 82, the kit in which the propagator-linking moiety is a thiol group or a dithiolan group.

[0402] Embodiment 84. In any one of embodiments 54 to 83, a kit selected from the group consisting of the following by the propagator:

[0403]

[0404] Embodiment 85. A kit in any one of embodiments 54 to 84, wherein the first reagent and the second reagent are contained in the same container.

[0405] Embodiment 86. A kit in any one of embodiments 54 to 84, wherein the first reagent and the second reagent are contained in separate containers.

[0406] Embodiment 87. Any one of embodiments 54 to 86, wherein the kit further comprises a payload, wherein the payload is a nucleic acid, compound, polypeptide, protein, glycan, or a combination thereof.

[0407] Embodiment 88. The kit of Embodiment 87, wherein the nucleic acid is RNA or DNA.

[0408] Embodiment 89. A kit according to Embodiment 88, wherein the payload codes for a polypeptide.

[0409] Embodiment 90. A kit in any one of embodiments 87 to 89, wherein the payload is immunogenic or the payload is a nucleic acid configured to code for an immunogenic polypeptide or protein.

[0410] Embodiment 91. A method for delivering a payload to a target, comprising administering to the target an effective amount of a pharmaceutical formulation containing a polymer some, wherein the polymer some comprises a membrane encapsulating the payload, and wherein the membrane comprises a copolymer of any one of Embodiments 1 to 34.

[0411] Embodiment 92. The method of Embodiment 91, wherein the copolymer occupies at least 50%, 70%, 80%, 90%, 95%, or 99% of the membrane.

[0412] Embodiment 93. A method according to Embodiment 92, wherein the copolymer is a first copolymer and the membrane further comprises a second copolymer, wherein the first copolymer and the second copolymer exist independently of any one of Embodiments 1 to 34.

[0413] Embodiment 94. A method in any one of embodiments 91 to 93, wherein the payload is a nucleic acid, compound, peptide, protein, glycan, or a combination thereof.

[0414] Embodiment 95. The method of Embodiment 94, wherein the nucleic acid is RNA or DNA.

[0415] Embodiment 96. The method of Embodiment 95, wherein the payload codes for a polypeptide.

[0416] Embodiment 97. A method in any one of embodiments 91 to 96, wherein the payload is immunogenic or the payload is a nucleic acid configured to code for an immunogenic polypeptide or protein.

[0417] Embodiment 98. A method in any one of embodiments 91 to 97, wherein the payload is a first payload and the membrane further encapsulates a second payload.

[0418] Embodiment 99. The method of Embodiment 98, wherein the second payload is a nucleic acid, compound, polypeptide, protein, glycan, or a combination thereof.

[0419] Embodiment 100. The method of Embodiment 99, wherein the first payload and the second payload are different.

[0420] Embodiment 101. A method for preventing or treating a disease in a subject, comprising administering to the subject an effective amount of a pharmaceutical formulation containing a polymerosome, wherein the polymerosome comprises a membrane containing a polymer component of any one of Embodiments 1 to 34; and a payload encapsulated within the membrane; wherein the payload is a therapeutic agent or induces a therapeutic agent.

[0421] Embodiment 102. The method of Embodiment 101, wherein the polymer element occupies at least 50%, 70%, 80%, 90%, 95%, or 99% of the membrane.

[0422] Embodiment 103. The method of Embodiment 101 or Embodiment 102, wherein the payload is a nucleic acid, compound, peptide, protein, glycan, or a combination thereof.

[0423] Embodiment 104. The method of Embodiment 103, wherein the nucleic acid is RNA or DNA.

[0424] Embodiment 105. The method of Embodiment 104, wherein the payload codes for a polypeptide.

[0425] Embodiment 106. A method in any one of embodiments 101 to 105, wherein the payload is a first payload and the membrane further encapsulates a second payload.

[0426] Embodiment 107. The method of Embodiment 106, wherein the second payload is a nucleic acid, compound, polypeptide, protein, glycan, or a combination thereof.

[0427] Embodiment 108. The method of Embodiment 107, wherein the first payload and the second payload are different.

[0428] Embodiment 109. A method in any one of embodiments 101 to 108, wherein a polymer swab is administered as an initial dose, followed by administration as 1, 2, 3, 4, 5 or more booster doses.

[0429] Embodiment 110. The method of Embodiment 109, wherein the booster dose is administered about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, or about 6 months or more after the initial dose.

[0430] Embodiment 111. A method in any one of Embodiments 101 to 110, wherein the effective amount is in the range of about 5 μg to 1000 μg.

[0431] Embodiment 112. A method for boosting an adaptive immune response comprising administering an effective amount of a pharmaceutical formulation containing a polymerosome to a subject, wherein the polymerosome comprises a membrane encapsulating a payload, wherein the membrane comprises a copolymer of any one of Embodiments 1 to 34; wherein the payload is immunogenic or induces an immunogenic biomolecule.

[0432] Embodiment 113. The method of Embodiment 112, wherein the polymer element occupies at least 50%, 70%, 80%, 90%, 95%, or 99% of the membrane.

[0433] Embodiment 114. The method of Embodiment 83 or Embodiment 84, wherein the payload is a nucleic acid, compound, peptide, protein, glycan, or a combination thereof.

[0434] Embodiment 115. The method of Embodiment 85, wherein the nucleic acid is RNA or DNA.

[0435] Embodiment 116. A method in any one of Embodiments 112 to 115, wherein the biomolecule is a polypeptide or a protein.

[0436] Embodiment 117. A method in any one of embodiments 112 to 116, wherein the payload is a first payload and the membrane further encapsulates a second payload.

[0437] Embodiment 118. The method of Embodiment 117, wherein the second payload is a nucleic acid, compound, polypeptide, protein, glycan, or a combination thereof.

[0438] Embodiment 119. The method of Embodiment 118, wherein the first payload and the second payload are different.

[0439] Embodiment 120. A method in any one of embodiments 112 to 119, wherein a polymer swab is administered as an initial dose, followed by 1, 2, 3, 4, 5 or more booster doses.

[0440] Embodiment 121. The method of Embodiment 120, wherein the booster dose is administered about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, or about 6 months or more after the initial dose.

[0441] Embodiment 122. A method in any one of Embodiments 112 to 121, wherein the effective amount is in the range of about 5 μg to 1000 μg.

Claims

Claim 1 A copolymer for forming a polymerosome, comprising: an initiator block comprising a glycan head; a propagator block comprising a functional moiety comprising a guanidine group, a zwitterion group, a diethylenetriamine, or a combination thereof; and a link that covalently links the initiator block and the propagator block and comprises a link comprising a disulfide bond. Claim 2 A copolymer according to claim 1, wherein the glycan head comprises a terminal mannoside. Claim 3 A copolymer comprising an O-aryl mannoside having a benzene ring in which the glycan head is optionally substituted, in accordance with claim 1. Claim 4 A copolymer according to claim 1, wherein the glycan head comprises a mono-mannosid, a di-mannosid, or a tri-mannosid. Claim 5 In paragraph 4, a copolymer in which the tri-mannosid is α-1,3-α-1,6-trimannosid. Claim 6 A copolymer according to claim 1, wherein the initiator block further comprises an initiator spacer comprising a saturated carbon moiety, a polyethylene glycol (PEG) moiety, or a combination thereof. Claim 7 A copolymer according to claim 1, wherein the glycan head is configured to bind to a dendritic cell. Claim 8 A copolymer according to claim 7, wherein the glycan head is configured to selectively bind to the DC-SIGN. Claim 9 In claim 8, the glycan head is K in the range of 5 to 8000 nM at pH 7.

4. D A copolymer configured to bond to a DC-SIGN. Claim 10 In paragraph 1, the glycan head is 9 BPC Neu5Ac conjugated N-glycan, Neu5Ac conjugated N-glycan, 9 TCC A copolymer comprising a Neu5Ac conjugated N-glycan or a combination thereof. Claim 11 A copolymer according to claim 1, wherein the initiator block is selected from the group consisting of: Here, the filled circle represents the mannosid, the empty circle represents the galactose, the filled square represents the GlcNAc, and the diamond represents the Neu5Ac. Claim 12 A copolymer according to claim 1, wherein the propagator block comprises more than one guanidine group. Claim 13 In paragraph 12, a copolymer in which the propagator block comprises three guanidine groups. Claim 14 A copolymer according to claim 1, wherein the propagator block comprises a propagator spacer comprising a saturated carbon moiety, a polyethylene glycol (PEG) moiety, or a combination thereof. Claim 15 The synthetic polymer according to claim 1, wherein the propagator block is a first propagator block, the linkage is a first linkage, and the copolymer further comprises a second propagator block connected to the first propagator block through a second linkage; wherein the first propagator block and the second propagator block independently comprise a guanidine group, a zwitterion group, a diethylenetriamine, or a combination thereof; and wherein the second linkage comprises a disulfide bond. Claim 16 A copolymer according to claim 15, wherein the first propagator block comprises a guanidine group and the second propagator block comprises a zwitterion group; or the first propagator block comprises a guanidine group and the second propagator block comprises diethylenetriamine. Claim 17 A copolymer in which the propagator block of paragraph 1 is selected from the group consisting of the following. Claim 18 In claim 17, a copolymer comprising at least two propagator blocks, wherein at least two propagator blocks are (1) PB1 and PB5, (2) PB1 and PB4, (3) PB2 and PB5, (4) PB2 and PB5, or (5) P1, P4 and P5. Claim 19 In paragraph 18, the initiator block and at least two propagator blocks are IB5-PB1 / PB5, IB5-PB1 / PB4, IB5-PB2 / PB5, IB5-PB2 / PB4, IB5-PB1 / PB4 / PB5, IB6-PB1 / PB5, IB6-PB1 / PB4, IB6-PB2 / PB5, IB6-PB2 / PB4, IB6-PB1 / PB4 / PB5, IB7-PB1 / PB5, IB7-PB1 / PB4, IB7-PB2 / PB5, IB7-PB2 / PB4, IB7-PB1 / PB4 / PB5, IB8-PB1 / PB5, IB8-PB1 / PB4, IB8-PB2 / PB5, A copolymer selected from the group consisting of IB8-PB2 / PB4, IB8-PB1 / PB4 / PB5, IB9-PB1 / PB5, IB9-PB1 / PB4, IB9-PB2 / PB5, IB9-PB2 / PB4, IB9-PB1 / PB4 / PB5, IB10-PB1 / PB5, IB10-PB1 / PB4, IB10-PB2 / PB5, IB10-PB2 / PB4 and IB10-PB1 / PB4 / PB5. Claim 20 A polymer swab comprising a membrane that defines an internal space, wherein the membrane comprises a copolymer of any one of claims 1 to 19. Claim 21 In paragraph 20, a polymer filament in which a membrane encapsulates a payload therein. Claim 22 In paragraph 21, a polymerosome in which the payload is a nucleic acid, compound, polypeptide, protein, glycan, or combination thereof. Claim 23 In paragraph 22, a polymerosome in which the nucleic acid is RNA or DNA. Claim 24 In paragraph 21, a polymerosome in which the payload is immunogenic or the payload is a nucleic acid configured to code for an immunogenic polypeptide or protein. Claim 25 A polymer som, wherein the copolymer is a first copolymer and the membrane further comprises a second copolymer, wherein the first copolymer and the second copolymer are independent of the first copolymer. Claim 26 A polymer some in which the payload is the first payload and the membrane additionally encapsulates the second payload in claim 21. Claim 27 A formulation comprising the polymer swab of claim 20. Claim 28 In claim 27, a formulation comprising 0.01 to 95% (w / w) of polymer pores. Claim 29 A formulation according to claim 27, wherein the polymer swab is a first polymer swab, and the composition further comprises a second polymer swab, wherein the first polymer swab and the second polymer swab differ in size, the copolymer forming the membrane thereof, the payload encapsulated within the polymer swab, or a combination thereof. Claim 30 In paragraph 27, a preparation further comprising pharmaceutically permissible excipients, azuvants, or combinations thereof.